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development. Defects were observed in the magnitude of the influenza-specific CD8+ T cell responses, as
well as in cytokine production and recall capacity. Similarly, during chronic LCMV infection, PD-1 deficient
CD8+ T cells were more dysfunctional than their WT counterparts. Permanent absence of PD-1
dramatically dysregulated lineage dynamics and long-term stability of exhausted CD8+ T cell populations
through a mechanism involving the transcription factors T-bet and Eomesodermin. As a result, PD-1
deficiency led to the accumulation of terminally-differentiated, but more cytotoxic, exhausted CD8+ T
cells. These findings reveal a novel dual role for PD-1 signals during acutely-resolved and chronic viral
infections. PD-1 pathway signals clearly restrict CD8+ T cell activation, expansion and function early,
consistent with previous work. However, in doing this, PD-1 also preserves the quantity and quality of
long-term memory or exhausted CD8+ T cell responses. Thus, PD-1 acts as a critical "rheostat" on CD8+ T
cells, balancing the need for activation to achieve pathogen clearance with the establishment and
maintenance of long-term memory or exhausted T cell responses.
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ABSTRACT
REGULATION OF ANTI-VIRAL CD8+ T CELL RESPONSES BY
THE PD-1 PATHWAY
Pamela M Odorizzi
E. John Wherry

PD-1 and its ligands, PD-L1 and PD-L2, constitute a critical immunoregulatory
pathway for modulating CD8+ T cell responses. This pathway has become an important
therapeutic target in cancer and chronic viral infections, where blockade of PD-1/PD-L1
reverses CD8+ T cell exhaustion and improves outcomes. However, it remains unclear
how PD-1 pathway signals shape the development and maintenance of memory CD8+ T
cell responses following acutely-resolved infection or exhausted CD8+ T cell responses
following chronic infection. Absence of PD-1 results in early over-activation, excessive
proliferation and diminished survival of virus-specific CD8+ T cells during both acutelyresolved and chronic viral infections. Following influenza infection, PD-1 pathway
deficiency led to sub-optimal CD8+ T cell memory development. Defects were observed
in the magnitude of the influenza-specific CD8+ T cell responses, as well as in cytokine
production and recall capacity. Similarly, during chronic LCMV infection, PD-1 deficient
CD8+ T cells were more dysfunctional than their WT counterparts. Permanent absence
of PD-1 dramatically dysregulated lineage dynamics and long-term stability of exhausted
CD8+ T cell populations through a mechanism involving the transcription factors T-bet
and Eomesodermin. As a result, PD-1 deficiency led to the accumulation of terminallydifferentiated, but more cytotoxic, exhausted CD8+ T cells. These findings reveal a novel
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dual role for PD-1 signals during acutely-resolved and chronic viral infections. PD-1
pathway signals clearly restrict CD8+ T cell activation, expansion and function early,
consistent with previous work. However, in doing this, PD-1 also preserves the quantity
and quality of long-term memory or exhausted CD8+ T cell responses. Thus, PD-1 acts
as a critical “rheostat” on CD8+ T cells, balancing the need for activation to achieve
pathogen clearance with the establishment and maintenance of long-term memory or
exhausted T cell responses.
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CHAPTER 1: Introduction
1.1: Global Heath Challenges: Infectious Disease
Infectious diseases place a significant burden on the health of individuals
worldwide, as well as on healthcare infrastructure and global economy. Much of this
burden is borne by developing countries, where poor sanitation and unsafe drinking
water propagate the spread of disease. However, even in developed countries, many
infectious diseases remain a considerable threat, particularly to the young and elderly.
Over the past 60 years, the public health and research communities have made
significant advances in the control and elimination of infectious diseases (Panhuis et al.,
2013). Arguably the most important medical intervention implemented has been
vaccinations. It is estimated that vaccines have prevented over 100 million cases of
disease in the United States and more than 2.5 million deaths worldwide (WHO, 2012).
Perhaps one of the most notable successes of vaccinations is the elimination of
smallpox in 1980 (Fenner et al.1988). However, infectious diseases are continually
emerging and re-emerging. In fact, since 1980, there has been an increase in the
number of new infectious agents, the number of outbreaks worldwide and also a
resurgence of known diseases (Smolinski, Hamburg, & Lederberg, 2003). Many of these
diseases cause significant mortality worldwide and challenge the current model of
vaccine development. For example, seasonal influenza, an acutely-resolved infection,
causes 3,000-49,000 deaths annually in the United States (CDC, 2010). Other
infections, such as human immunodeficiency virus (HIV) and hepatitis C virus (HCV),
often cause chronic disease and death in patients. As of 2012, 35.3 million people were
living with HIV, leading to 1.6 million HIV-related deaths per year (UNAIDS, 2013). In the
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United States, there are over 3.2 million people chronically infected with HCV, resulting
in approximately 16,000 deaths each year (CDC, 2011). While anti-viral drugs and other
strategies can lower viral load and extend life span in many patients with chronic HIV,
there are currently no medical interventions that can reliably cure this infection (Piacenti,
2006). The recent introduction of direct-acting anti-viral drugs against HCV may provide
a potential cure for some chronic HCV patients; however, the high cost of treatment
makes this approach unattainable for many (Kiser and Flexner, 2013). Thus, a major
goal remains the development of prophylactic vaccination strategies that can protect
against these public health threats. Given the ineffectiveness of implementing our
current vaccine platforms, an important next step is defining the adaptive immune
components that contribute to effective immune responses against these diseases.

1.2: The Adaptive Immune System
The adaptive immune system possesses the unique properties of diversity,
specificity and memory. These properties allow the adaptive immune response to
combat many different pathogens in a specific and targeted way, maximizing pathogen
clearance and minimizing damage to the host. In addition, this strategy provides
adaptive immune cells with the knowledge to “remember” a pathogen encounter and
results in better protection against a pathogen upon subsequent exposure (Ahmed and
Gray, 1996; Williams and Bevan, 2007). There are two major cell types that make up the
adaptive immune system: B cells and T cells. Both cell types undergo genomic
rearrangement to generate millions of unique surface receptors, known as B cell
receptors (BCR; also known as antibodies) and T cell receptors (TCR). Each B cell and
T cell expresses one unique version of a BCR or TCR, respectively, which generates a
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repertoire of adaptive immune cells with immense diversity (Wong and Pamer, 2003;
Zhang and Bevan, 2011).
The primary role of B cells is production of soluble antibodies that specifically bind
intact pathogen proteins. While B cells are critical for neutralizing infectivity of
pathogens, T cells are required for clearance of a pathogen after the establishment of
infection. Broadly speaking, T cells can be sub-divided into CD4+ or CD8+ T cells.
CD4+ T cells, or T helper cells, determine the type of immune response that will be
mounted against an invading pathogen through production of distinct cytokines, as well
as via specific interactions with other immune cells. CD8+ T cells, or cytotoxic T cells
(CTLs), kill pathogen-infected cells through the recognition of short viral peptide
fragments presented on the surface of infected cells in the context of major
histocompatibility complex (MHC) (Zinkernagel and Doherty, 1974; Rock and Goldberg,
1999). Collectively, B cells, CD4+ T cells and CD8+ T cells mount a coordinated immune
response against an invading pathogen.

1.3: CD8+ T cells
The critical role of CD8+ T cells during infection has been demonstrated in many
mouse models where loss of CD8+ T cell effector functions leads to impairment in
pathogen control. For example, mice deficient in the cytotoxic molecule perforin or the
effector cytokine IFN-γ (discussed below) have defective CD8+ T cell responses that
correlate with increased pathogen burden (Walsh et al., 1994; Matloubian et al., 1999;
Dorman et al., 1999; Binder and Griffin, 2001; Bartholdy et al., 2000). Similarly, depletion
of CD8+ T cells during undetectable, chronic SIV infection of rhesus macaques leads to
rebound of the virus to high circulating levels (Jin et al., 1999; Schmitz et al., 1999).
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Restoration of viral control in this setting is associated with the re-population of the CD8+
T cell compartment. HIV and the progression to acquired immunodeficiency syndrome
(AIDS) is also associated with loss of CD8+ T cell populations and effector functions
(Shankar et al., 2000; Appay et al., 2000; Kostense et al., 2002; Gruener et al., 2001b;
Maini et al., 1999). As a result, late-stage HIV patients are more susceptible to new
infections, as well as re-activatoin of latent infections, including herpes viruses (Siegal et
al., 1981; Kaplan et al., 2000). Thus, CD8+ T cell anti-viral activities are associated with
control of disease in both mice and humans.

1.3.1: Initiation of CD8+ T cell Responses
Naïve CD8+ T cells become activated upon encounter with an antigen-presenting
cell (APC) that is presenting pathogen-derived peptide in the context of MHC on its
surface (signal 1) (Smith-Garvin et al., 2009). Co-stimulation (signal 2) fine-tunes TCR
signaling through positive signals from molecules, such as CD28, ICOS, 4-1BB, CD27
and many others (Crawford and Wherry, 2009; Chen and Flies, 2013). These costimulatory signals augment and sustain T cell activation that is initiated by the TCR
through a variety of mechanisms. For example, co-stimulation is known to augment
cytokine and chemokine production, promote expression of anti-apoptosis proteins (such
as Bcl-xL) and upregulate growth factor receptors (Chen and Flies, 2013; June et al.,
1987; Boise et al., 1995; Acuto and Michel, 2003). In addition, co-stimulation plays a
critical role in regulating the metabolism of CD8+ T cells. For example, CD28 induces
signaling through the P13K-Akt-mTor pathway, which, among other things, promotes
glucose transport and protein synthesis in newly activated CD8+ T cells (McAdam et al.,
1998; Stein et al., 1994; Boomer and Green, 2010; Frauwirth et al., 2002). The positive
signals propagated by co-stimulatory receptors are also counter-balanced by negative
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signals from inhibitory receptors (discussed in detail below). Finally, optimal CD8+ T cell
activation also requires signals from inflammatory cytokines (signal 3), such as IL-12,
type 1 interferons, and TLR ligands (Curtsinger and Mescher, 2010; Curtsinger et al.,
2003, 2005; Valenzuela et al., 2002). The coordinated integration of these three signals
is critical for generation of functional CD8+ T cells and, importantly, the quantity and
quality of each signal can dramatically impact the type of response that is mounted.
Following activation, naïve CD8+ T cells expand and differentiate into a pool of
effector cells. Proliferation of CD8+ T cells is extremely robust after pathogen encounter,
with CD8+ T cells undergoing up to a 50,000-fold expansion (Badovinac et al., 2007;
Zhang and Bevan, 2011). This proliferation is accompanied by migration to sites of
infection and acquisition of properties to fight an invading pathogen. These properties
include cytotoxic ability and production of pro-inflammatory cytokines. The killing of
infected cells by CD8+ T cells can be executed by two major mechanisms:
perforin/granzyme and Fas/FasL interactions (Kägi et al., 1995, 1994). Release of
perforin at a target cell leads to the formation of a pore in the target cell membrane. This
pore then allows for entry of granzymes into the cell that induce cell death of a
pathogen-infected cell (Heusel et al., 1994; Kägi et al., 1996). Alternatively, the Fas
death receptor pathway can be activated through Fas/FasL interactions, resulting in
programmed death of an infected cell (Kägi et al., 1995, 1994). Co-production of multiple
pro-inflammatory cytokines is another critical function of CD8+ T cells. Cytokines such
as IL-2, TNF-α, Mip-1α, and IFN-γ augment immune responses while inducing an antiviral state (Harty and Bevan, 1999; Cocchi et al., 1995; Guidotti and Chisari, 2001).
Following expansion, 90-95% of effector cells will die by apoptosis during the contraction
phase (Badovinac et al., 2002). Depending on the type of infection, subsequent
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differentiation of CD8+ T cells into memory cells or exhausted cells will follow (Figure
1.1).
Differentiation of CD8+ T cells from naïve to effector cells is accompanied by
dramatic changes in gene expression profiles, which are regulated by key transcription
factors. A central regulator of CD8+ T cell effector differentiation appears to be BATF, a
basic leucine zipper transcprion family member (Kurachi et al., 2014). Kurachi et al.
demonstrated that, in the absence of BATF, CD8+ T cells undergo a dramatic metabolic
crash that prevents subsequent differentiation and expansion into effector cells. BATF,
along with IRF4, regulates effector differentiation by promoting the expression of the
transcription factors Tbet, Blimp-1 and Runx3 (Kurachi et al., 2014). Notch has also
recently been implicated as a key “hub” for integration of signals to promote CD8+ T cell
effector differentiation. These studies indicate that Notch forms a critical feedback loop
with CD25 (IL-2Ra), Tbet and mTOR to drive differentiation of effector cells (Backer et
al., 2014). Early expression of Tbet induced by TCR signaling, as well as BATF and
Notch, has been shown to play a key role in the early induction of IFN-γ expression
(Cruz-Guilloty et al., 2009; Backer et al., 2014). Subsequent expression of Runx3 and
Blimp-1 re-enforces IFN-γ expression while also inducing the expression of cytotoxic
molecules, such as granzyme B. Runx3 also induces the expression of the transcription
factor Eomesodermin (Eomes), which controls expression of perforin and seems critical
for late IFN-γ expression (Cruz-Guilloty et al., 2009; Pearce et al., 2003). Importantly,
naïve CD8+ T cells that lack Tbet, Blimp-1, Notch 1/2, or Runx3 show defects in effector
responses, including proliferation, cytotoxicity, and cytokine production (Chang et al.,
2014; Angelosanto and Wherry, 2010; Cruz-Guilloty et al., 2009; Pearce et al., 2003;
Backer et al., 2014). Thus, effector CD8+ T cell differentiation requires the temporal
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induction of key transcription factors that regulate gene expression of effector molecules.
In addition, these transcription factors play a central role in the fate of effector cells in
acutely-resolved and chronic infections.

1.3.2: Generation of CD8+ T cell Memory after Acutely-Resolved Infections
Expansion and differentiation of CD8+ T cells results in the generation of a
phenotypically and functionally heterogenous pool of effector cells during acutelyresolved infections. The majority of the effector cell population is comprised of shortlived effector cells (SLECS), while a smaller population of memory precursor cells also
exist. Studies of acute lymphocytic choriomeningitis virus (LCMV) and Listeria
monocytogenes (L. monocytogenes) infections in mice found that SLECs could be
readily identified by high expression of KLRG-1 and low expression of CD127 (IL-7R)
(Joshi et al., 2007; Obar et al., 2011). In addition to this defining phenotype, SLECs also
have higher expression of the transcription factors Tbet and Blimp-1, which corresponds
with increased effector molecules, greater migration into non-lymphoid tissues and the
more terminally-differentiated state of these cells (Rutishauser et al., 2009; Kallies et al.,
2009; Pearce et al., 2003; Intlekofer et al., 2005). During the contraction phase, the
majority of SLECs will die by apoptosis, whereas memory precursor cells will persist and
differentiate into long-lived memory cells. In contrast to SLECs, memory precursor cells
are KLRG-1lo IL-7Rhi and memory differentiation of these cells is associated with higher
levels of the transcription factors Eomes, Tcf-1, Foxo1, and Id3 (Joshi et al., 2007;
Kaech et al., 2003a; Zhou et al., 2010; Hess Michelini et al., 2013; Kim et al., 2013;
Yang et al., 2011; Intlekofer et al., 2005).
Memory CD8+ T cells acquire several cardinal properties that endow them with the
ability to more quickly and effectively respond to a secondary encounter with a pathogen
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(Figure 1.1). These properties include rapid reactivation of effector functions, robust
proliferation and enhanced homing to secondary lymphoid organs (Wherry and Ahmed,
2004; Kaech et al., 2002; Bevan, 2011). In addition, memory cells persist via antigenindependent, cytokine-driven homeostatic proliferation in response to IL-7 and IL-15
(Kaech et al., 2003b). Given the heterogeneity of effector CD8+ T cells, it is not
surprising that many sub-populations of memory cells also exist (Huster et al., 2004;
Kaech et al., 2003b; Hamann et al., 1997). The most notable of these are central
memory T cells (Tcm), effector-memory T cells (Tem), tissue-resident memory cells
(Trm) and stem memory T cells (Tsm) (Sallusto et al., 1999; Hamann et al., 1997;
Carbone et al., 2013; Turtle et al., 2009; Zhang et al., 2005). Generally, Tcm are
CD62Lhi CCR7hi, which leads to increased retention of these cells in lymphoid tissue. In
contrast, Tem are CD62Llo CCR7lo, which endows them with the ability to circulate
through non-lymphoid tissues more readily. Tem are also thought to be more “effector”
like, possessing greater cytotoxicity (Wherry et al., 2003b; Wherry and Ahmed, 2004).
The signals that govern and shape memory CD8+ T cell development remain
poorly understood. One factor that seems to play an important role in the generation of
memory cells is the strength and duration of antigenic stimulus. This includes the
strength of TCR:pepide-MHC interactions, as well as the collective input from costimulatory, inhibitory and inflammatory signals (Iezzi et al., 1998; Tubo et al., 2013). For
example, the cytokine milieu and inflammatory environment have been shown to
influence the acquisition of CD8+ T cell memory properties (Plumlee et al., 2013). IL12R-deficiency or Tbet-deficiency in mice leads to more rapid development of memory
characteristics during L. monocytogenes infection (Takemoto et al., 2006). The mTOR
pathway, which is upregulated by TCR and co-stimulatory signals, also controls effectormemory differentiation. LCMV-infected mice who received low does treatment with
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rapamycin, an inhibitor of mTOR signaling, had enhanced generation of MPECs during
the expansion phase as well as accelerated development of memory properties (Araki et
al., 2009). Nevertheless, exactly how signals 1, 2 and 3 contribute to the differentiation
of memory CD8+ T cells remains unclear.

Figure 1.1
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Figure 1.1: Model of CD8+ T cell memory versus exhaustion during acute and
chronic viral infection. Naïve CD8+ T cells become activated, leading to proliferation
and differentiation into a pool of effector CD8+ T cells. During acutely-resolved infection,
effector CD8+ T cells facilitate pathogen clearance after which most short-lived effector
cells will die. Memory precursor cells will transition into a pool of long-lived memory
CD8+ T cells that acquire cardinal memory properties, such as homeostatic proliferation
and recall capacity. In contrast, failure to achieve pathogen clearance results in
sustained antigen loads and inflammation that result in exhausted CD8+ T cell
responses. Exhausted CD8+ T cells are characterized by loss of effector functions and
antigen-driven proliferation.
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1.3.3: CD8+ T cell Exhaustion and the Response to Chronic Infection and
Cancer
During chronic infections, pathogen-specific CD8+ T cells are initially activated and
gain effector functions; however these cells become progressively dysfunctional, or
exhausted, over time (Zajac and Ahmed, 1998; Gallimore and Zinkernagel, 1998;
Wherry, 2011). Exhaustion of CD8+ T cells during chronic infection is hierarchical, with
early defects in proliferation, IL-2 production, and cytotoxicity, followed by the loss of
TNF-α, IFN-γ, and β-chemokine production at late stages (Wherry et al., 2003a).
Ultimately, exhausted CD8+ T cells can be physically deleted (Figure 1.1). The severity
of CD8+ T cell exhaustion correlates with the strength and duration of antigen
stimulation. For example, high levels of persistent epitope presentation during chronic
LCMV infection in mice leads to severe exhaustion and physical deletion of
corresponding epitope-specific CD8+ T cells. In contrast, in the same mice, epitopes that
are presented at lower levels of stimulation induce less severe exhaustion of their
respective epitope-specific CD8+ T cells (Wherry et al., 2003a). Viral load during chronic
infection also correlates with the severity of CD8+ T cell exhaustion (Fuller and Zajac,
2003; Wherry et al., 2003a; Virgin et al., 2009).
CD8+ T cell exhaustion was first described during chronic LCMV infection in mice;
however, similar dysfunction has now been described in many human chronic infections,
including HIV, HCV, HBV and others (Zajac and Ahmed, 1998; Gallimore and
Zinkernagel, 1998; Moskophidis et al., 1993; Boni et al., 2007; Urbani et al., 2006). In
addition, exhausted CD8+ T cells have also been identified in many cancer models, as
well as in human cancer patients (Blank et al., 2004; Iwai et al., 2002; Muenst et al.,
2013, 2010). Along with loss of poly-functionality, exhausted CD8+ T cells have several
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other defining features. These include the up-regulation of negative regulatory pathways,
altered expression of key transcription factors and antigen-dependent maintenance.
First, exhausted CD8+ T cells aberrantly express high levels of multiple inhibitory
receptors (discussed below) (Crawford and Wherry, 2009; Wherry et al., 2007;
Blackburn et al., 2009). Immunoregulatory cytokines, such as IL-10 and TGF-β, have
also been shown to contribute to CD8+ T cell dysfunction during chronic infection
(Brooks et al., 2006; Tinoco et al., 2009; Wherry, 2011). Second, exhausted CD8+ T
cells have a unique gene expression profile that is regulated by altered expression of
effector- and memory-associated transcription factors (Wherry et al., 2007; Chang et al.,
2014). For example, Blimp-1 is associated with terminal-differentiation of effector cells
during acutely-resolved infection; however, elevated and sustained expression of Blimp1 is associated with dysfunction of exhausted CD8+ T cells (Rutishauser et al., 2009;
Kallies et al., 2009; Shin et al., 2009). Dysregulation of the central transcription factor
BATF also seems to occur during T cell exhaustion (discussed below) (Quigley et al.,
2010). In addition, Tbet and Eomes have been demonstrated to play critical roles in
distinct subsets of exhausted CD8+ T cells during chronic infection (Kao et al., 2011;
Paley et al., 2012). How these transcription factors cooperate to regulate gene
expression and function of exhausted CD8+ T cells remains poorly understood. Finally,
CD8+ T cell exhaustion is accompanied by the loss of classical memory properties,
including poor antigen-independent maintenance and lack of responsiveness to IL-7 and
IL-15 (Wherry et al., 2004). As a result, exhausted CD8+ T cells become “addicted” to
antigen for survival and proliferation throughout the course of a chronic infection (Shin et
al., 2007). Recent work has further characterized the mechanism responsible for longterm proliferation of exhausted CD8+ T cells. Subsets of exhausted CD8+ T cells exist in
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a progenitor-progeny relationship and cooperate to balance continued proliferation with
maintenance of CD8+ T cells for many years. High levels of Tbet expression and low
levels of Eomes expression maintain the progenitor subset of exhausted CD8+ T cells.
These Tbethi cells have the ability to self-renew and also, through a process of extensive
proliferation, give rise to progeny that are maintained by high expression of Eomes. In
contrast to Tbethi progenitor cells, Eomeshi cells cannot self renew and are more
terminally-differentiated. These subsets have distinct phenotypic and functional
properties (discussed below) and both are critical for durability of exhausted CD8+ T cell
responses (Paley et al., 2012). The signals that regulate the establishment and
maintenance of this progenitor-progeny relationship during chronic infection are unclear.

1.4: Inhibitory Receptors on Lymphocytes
Co-stimulatory and inhibitory receptors are critical regulators of adaptive immune
cell function. In general, signal 2 from co-stimulation fine tunes TCR signaling through
positive signals from molecules, such as CD28, ICOS, 4-1BB, CD27 and many others
(Chen and Flies, 2013). These co-stimulatory signals can augment survival, T cell
function, enhance metabolic activity of developing effector T cells and generally promote
sustained responses. However, negative signals from inhibitory receptors, such as
CTLA-4, PD-1 and others, balance and tune these positive signals from TCR and/or costimulation. A central role for inhibitory receptors is the regulation of autoimmunity and
tolerance (Francisco et al., 2010). It is not surprising, therefore, that deficiencies in many
inhibitory receptor pathways have been associated with autoimmunity in mice, including
CTLA-4, PD-1 and others (Waterhouse et al., 1995; Tivol and and Sharpe, 2004;
Nishimura and Honjo, 1998; Nishimura et al., 1999, 2001). Polymorphisms in inhibitory
receptor genes are also associated with susceptibility to several human autoimmune
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diseases, including diabetes, multiple sclerosis, and rheumatoid arthritis (James et al.,
2005; Zhang et al., 2012; Velázquez-Cruz et al., 2007). This negative regulatory system
has been co-opted, and perhaps diversified, to temper the immune response to
infections, tumors, allografts, and perhaps even allergens (Keir et al., 2008). In many
settings, efficient negative regulation by inhibitory receptor pathways may be critical to
restrain and terminate immune responses, particularly those that could result in
immunopathology. However, inhibitory receptors have also been shown to hinder the
effective immune responses needed to clear some pathogens and tumors.

1.5: The Programmed Death-1 Pathway
The Programmed Death-1 (PD-1) pathway consists of the inhibitory receptor PD1 and its ligands PD-L1 (B7-H1) and PD-L2 (B7-DC) (Ishida et al., 1992; Freeman et al.,
2000a; Latchman et al., 2001). PD-1, a member of the immunoglobulin (Ig) superfamily,
is a 288 amino acid, type 1 transmembrane protein encoded by the PDCD1 gene.
Structurally, PD-1 is composed of an N-terminal IgV-like domain, a short stalk region, a
transmembrane domain and a cytoplasmic tail. The cytoplasmic tail of PD-1 contains two
tyrosine-based signaling motifs: an immunoreceptor tyrosine-based inhibition motif
(ITIM) followed by an immunoreceptor tyrosine-based switch motif (ITSM) (Chemnitz et
al., 2004; Okazaki et al., 2001; Zhang et al., 2004; Riley, 2009). PD-1 is expressed
during thymic development on immature CD4- CD8- thymocytes and is inducibly
expressed in the periphery on T cells, B cells, some NK cells and myeloid cells upon
activation (Agata et al., 1996; Nishimura et al., 1996). Induction of PD-1 expression
occurs by multiple mechanisms in different cell types. Signaling via the T cell receptor
(TCR) or B cell receptor (BCR) induces upregulation of PD-1 expression within a few
hours on T cells and B cells, respectively (Agata et al., 1996; Nishimura et al., 1996).
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PD-1 expression is also induced by common γ-chain cytokines, including IL-2, IL-7, IL15, and IL-12, or by IFN-α in some settings (Kinter et al., 2008; Terawaki et al., 2011).
The expression profiles of the PD-1 ligands, PD-L1 and PD-L2, differ
dramatically. PD-L1 is expressed ubiquitously by many cell types, including myeloid cells
(DCs and macrophages), B cells, T cells, stromal cells and a range of non-hematopoietic
cells. PD-L2 expression is restricted primarily to professional antigen-presenting cells,
such as DCs, macrophages and some B cells (Eppihimer et al., 2002; Yamazaki and
Yagita, 2002; Keir et al., 2008). Of note, both PD-L1 and PD-L2 have binding partners in
addition to PD-1. PD-L1 can also interact with B7-1 and PD-L2 with RGMb (Butte et al.,
2007; Xiao et al., 2014). Inflammatory signals seem to regulate the expression of PD-L1
and PD-L2 in most cell types. Type I and II interferons induce expression of PD-L1 via
two interferon regulatory factor-1 (IRF-1) bindings sites upstream of the transcriptional
start site (Lee et al., 2006; Liang et al., 2003). Cytokine signaling also regulates
expression of PD-L1 and PD-L2 (Loke and Allison, 2003).

1.5.1: PD-1 Signaling in T cells
PD-1 primarily mediates its inhibitory effects via the local and transient
intracellular attenuation of positive signals from activating receptors, including TCR/CD3
and co-stimulatory receptors. Upon ligation, both the ITIM and ITSM within the
cytoplasmic domain of PD-1 are phosphorylated, leading to recruitment of Src homology
2 (SH2) domain-containing tyrosine phosphatases (Parry and Riley, 2005; Okazaki et
al., 2001; Riley, 2009). In T cells, mutagenesis and microscopy studies have implicated
the interaction between phosphorylated ITSM and the phosphatase SHP2 as critical for
PD-1 inhibitory function (Parry and Riley, 2005; Yokosuka et al., 2012). SHP2 can then
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mediate the dephosphoryation of signaling molecules downstream of TCR/CD3 and
CD28, including CD3z, Zap70, and PKCθ (Parry and Riley, 2005; Yokosuka et al., 2012;
Riley, 2009). PD-1 also inhibits both the PI3K-Akt and Ras-MEK-ERK pathways, which
dramatically impacts glucose metabolism and cell cycle regulation (Parry and Riley,
2005; Patsoukis et al., 2012). Recent work in primary CD4+ T cells has demonstrated
that PD-1 inhibits cell cycle progression through the G1 phase by preventing the
activation of cyclin-dependent kinases (Cdks). PD-1 signaling can directly affect the
expression, phosphorylation and degradation of key cell-cycle regulators (Patsoukis et
al., 2012). Importantly, CD28 and/or IL-2 can override some, but not all, of PD-1
mediated inhibitory effects (Parry and Riley, 2005; Bennett et al., 2003; Freeman et al.,
2000a). Thus, PD-1 causes a broad, quantitative reduction in TCR/CD3 activationinduced signal transduction and downstream gene expression. In addition, by interfering
with co-stimulatory signaling pathways, PD-1 also hampers T cell metabolism, which has
profound consequences on proliferation and survival.
Recently, other mechanisms of PD-1 mediated inhibition in T cells have also
been elucidated. Using integrated genomic approaches, PD-1 signaling was shown to
upregulate the expression of BATF in exhausted T cells from humans chronically
infected with HIV and mice chronically infected with LCMV. Over-expression of BATF in
primary human T cells reduced proliferation and IL-2 secretion upon stimulation.
Conversely, effector functions could be rescued in exhausted T cells by shRNAmediated silencing of BATF, further supporting an inhibitory function of BATF in T cells
(Quigley et al., 2010). Thus, a mechanism of PD-1 inhibition may be to promote the
aberrant upregulation of BATF expression in exhausted CD8+ T cells, which, in turn, has
negative functional consequences. These findings suggest that inhibitory receptors not
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only blunt positive signaling events from TCR and co-stimulatory receptors, but may also
be capable of inducing transcriptional pathways that actively regulate immune cell
function. Since BATF might not only act as a dominant negative regulator of normal AP1 activity, but also have unique transcriptional activity, this mechanism of inhibitory
receptor activity also suggests the potential to influence cellular differentiation.

1.5.2: Regulation of Effector and Memory CD8+ T cells by the PD-1
Pathway
PD-1 and its ligands are rapidly upregulated upon activation and throughout the
effector phase of immune responses to acutely-resolved infections. Following antigen
clearance, however, expression of PD-1 decreases to low levels similar to that on naïve
CD8+ T cells (Barber et al., 2006; Brown et al., 2010). The potent ability of PD-1 to
modulate TCR and co-stimulatory signals suggests that the PD-1 pathway could have
both short-term and/or long-term consequences on CD8+ T cell responses to acutelyresolved infections. For example, PD-1 could regulate the activation and expansion of
CD8+ T cells during the effector phase, as well as the differentiation of CD8+ T cells into
long-lived memory cells. In addition, PD-1 pathway signals on CD8+ T cells, as well as
other immune cells, could substantially alter the pathogenesis and outcome of infection.
Many groups have investigated the role of the PD-1 pathway in various settings of
acutely-resolved infection using mice genetically deficient in PD-1 or PD-L1, as well as
through the use of monoclonal blocking antibodies. In some cases, loss of PD-1 signals
increases the effectiveness of anti-pathogen immune responses. For example, knocking
out or blocking the PD-1 pathway in mice increases effector CD8+ T cell responses and
survival following infection with Histoplasma capsulatum, rabies virus, human
metapneumovirus (HMPV), influenza virus or respiratory syncytial virus (Lázár-Molnár et
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al., 2008; Lafon and Wiendl, 2008; Erickson et al., 2012; Telcian et al., 2011). However,
PD-1 pathway deficiency has also been shown to be detrimental in some settings of
acutely-resolved infection. Although PD-1–deficient mice can more efficiently clear
adenovirus from the liver than wild-type mice, they also develop more severe
hepatocellular injury, likely due to an overaggressive adaptive immune response (Iwai et
al., 2003). Other studies showed that the absence or blockade of PD-L1 reduced effector
CD8+ T cell responses to L. monocytogenes in mice. In these examples, PD-L1 on
innate immune cells, such as DCs and macrophages, plays an important role in CD8+ T
cell activation and survival (Rowe and Sing Way, 2008; Talay et al., 2009; Yamazaki and
Okumura, 2005; Yao et al., 2009). Thus, the PD-1 pathway seems to restrict effector
CD8+ T cell responses during acutely-resolved infection. In some settings, this prolongs
pathogen clearance, however, can promote the survival of highly activated effector
CD8+ T cells and prevent detrimental immunopathology.
The PD-1 pathway has also been shown to regulate the differentiation and
development of memory CD8+ T cells following acutely-resolved infections. Similar to
regulation of the effector response by PD-1, there is conflicting data about how PD-1
pathway signals skew memory differentiation. Transient blockade of PD-1 signals can
improve recall responses of memory CD8+ T cells in some settings (Erickson et al.,
2012, 2014). There is also evidence that genetic absence of PD-1 can skew memory
CD8+ T cell differentiation towards either effector memory or central memory
phenotypes in different contexts. Allie et al demonstrated that PD-1 pathway deficiency
leads to enhancement of the quantity and quality of memory CD8+ T cell responses. In
addition, these memory CD8+ T cells were skewed towards a central memory
phenotype, with elevated expression of CD62L and CCR7 (Allie et al., 2011). In contrast,
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other studies have demonstrated that PD-1 deficiency results in accumulation of effector
memory CD8+ T cells that are CD62Llo CCR7lo (Charlton et al., 2013).
Thus, the precise role of PD-1 in regulating CD8+ T cell responses to acutelyresolved infections remains unclear. It is likely that the strength and duration of antigen
stimulation, as well as the amount of inflammation, induced by different pathogens
dramatically impacts how PD-1 regulates CD8+ T cell effector and memory formation
(Obar and Lefrançois, 2010; Joshi et al., 2007; Kaech and Ahmed, 2001). In addition to
regulating CD8+ T cell responses, the PD-1 pathway also appears critical for prevention
of immunopathology during many acutely resolved infections, particularly for pathogens
that infect sensitive tissues, such as the lung, liver, and brain (Iwai et al., 2003; Barber et
al., 2006; Frebel et al., 2012; Lafon and Wiendl, 2008). Chapter 2 in this thesis will
investigate the role of PD-1 in effector and memory development to acutely-resolved
viral infection.

1.5.3: Regulation of Exhausted CD8+ T cells by the PD-1 pathway
In contrast to acutely-resolved infections where PD-1 expression is transient,
expression of PD-1 is highly elevated and sustained on exhausted CD8+ T cells for
many months or years during chronic infection and cancer (Barber et al., 2006; Freeman
et al., 2006; Blank et al., 2005; Wherry, 2011). Expression of PD-L1 and PD-L2 also
remains elevated in these settings of sustained inflammation, particularly in the tumor
microenvironment or in organs that harbor high pathogen loads (Blank et al., 2005;
Blackburn et al., 2010b). This high level of PD-1/PD-L expression has profound
consequences on anti-viral and anti-tumoral CD8+ T cell responses, which, in turn,
influences the outcome of chronic infections and cancers. For example, high PD-1
expression on T cells has been shown to correlate with disease progression in several
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human chronic infections, including HIV and HCV (Day et al., 2006; Freeman et al.,
2006; Urbani et al., 2006). In addition, expression of PD-L1 on tumors corresponds with
poor prognosis in many cancer settings (Muenst et al., 2013, 2010; Kozako et al., 2009;
Topalian et al., 2012). The profound negative consequences of high PD-1/PD-L
expression on exhausted CD8+ T cells has been demonstrated in many settings of
chronic infection and cancer. Barber et al demonstrated that in vivo antibody-mediated
blockade of the PD-1 pathway during chronic LCMV infection in mice significantly
improves the magnitude and functionality of virus-specific CD8+ T cell responses.
Administration of anti-PD-L1 blocking antibody resulted in virus-specific CD8+ T cells
with improved cytokine production and cytotoxicity, which corresponded with a
significant decline in viral loads (Barber et al., 2006). Soon thereafter, several groups
showed upregulation of PD-1 expression on exhausted CD8+ T cells during human
chronic viral infections, such as HIV, HCV, and HBV, and demonstrated improved
function of T cells following in vitro PD-1/PD-L1 blockade or in vivo blockade of the PD-1
pathway in SIV-infected primates (Day et al., 2006; Freeman et al., 2006; Urbani et al.,
2006; Maini et al., 1999; Velu et al., 2009). Increased expression of PD-1 and its ligands
also impairs the effector responses against other persisting pathogens, such as
Helicobacter pylori, Mycobacterium tuberculosis, Schistosoma mansoni, Leishmania
donovani, and Toxoplasma gondii (Wu et al., 2010; Jurado and Garcia, 2008; LázárMolnár et al., 2010; Liang et al., 2006; Bhadra et al., 2011). In mouse tumor models,
similar improvements in exhausted CD8+ T cell functions have been demonstrated with
loss of PD-1/PD-L signals. For example, knocking out or blocking PD-1 increases antitumor CD8+ T cell responses and improves survival in models of melanoma, renal cell
carcinoma, and others (Blank et al., 2004, 2005; Okazaki et al., 2013). Thus, the PD1/PD-L pathway is a central negative regulator of exhausted CD8+ T cells during
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persisting infections and cancer. However, the mechanisms by which PD-1 regulates the
development and maintenance of exhausted CD8+ T cells remain unclear. Chapter 3 of
this thesis will investigate the role of PD-1 in the induction of CD8+ T cell exhaustion.
Recent work has begun to elucidate the nuances of PD-1 regulation of exhausted
CD8+ T cells (Blackburn et al., 2008; Paley et al., 2012; Kao et al., 2011). For example,
Tbethi and Eomeshi subsets of exhausted CD8+ T cells express different levels of PD-1
during chronic infection. Tbethi progenitor cells express intermediate levels of PD-1.
These PD-1int Tbethi cells reside mainly in lymphoid tissues and maintain some ability to
produce cytokines. While they possess low intrinsic turnover, PD-1int Tbethi cells can
robustly proliferate to give rise to a large population of CD8+ T cells that express high
levels of PD-1 and the transcription factor Eomes. PD-1hi Eomeshi cells abundantly
populate non-lymphoid organs, co-express several other inhibitory receptors and, while
they are less efficient cytokine producers, maintain the ability to kill. The cooperative
balance between PD-1int Tbethi progenitor cells and PD-1hi Eomeshi progeny cells is
critical for long-term maintenance of CD8+ T cell responses to chronic LCMV infection in
mice (Paley et al., 2012). Importantly, while PD-1int Tbethi cells are partially rescued by
in vivo PD-1/L1 blockade, PD-1hi Eomeshi cells appear more terminally-differentiated and
unresponsive to in vivo PD-1 pathway blockade (Blackburn and Wherry, 2008). Similar
subsets of Eomeshi and Tbethi CD8+ T cells have also been identified during chronic
HCV and HIV infections (Paley et al., 2012; Buggert et al., 2014). How PD-1 regulates
these different subsets of exhausted CD8+ T cells remains unclear. Chapter 3 in this
thesis will extend our understanding of the role of PD-1 on Tbethi and Eomeshi cells.

20

1.5.4: Clinical Use of PD-1 Pathway Blockade
Recent clinical trials have extended many of these observations from mouse
models to humans, demonstrating a potent ability of PD-1 pathway blockade to revitalize
anti-tumor immunity in late-stage cancer patients. Phase 1 clinical trials with a fully
human IgG4 anti-PD-1 antibody (nivolumab: Bristol-Myers Squibb) began in 2006.
Tumor regression was observed by 18% of patients with non-small-cell lung cancer,
28% of patients with melanoma, and 27% of patients with rencal cell carcinoma, with
very few immune-related toxicities observed (Topalian et al., 2012). Similar results were
obtained around the same time in clinical trials using a fully human antibody against PDL1 (Brahmer et al., 2012). Clinical responses were associated with infiltration of
lymphocytes into metastatic tumors and with the expression of PD-L1 by tumors
(Brahmer et al., 2012; Topalian et al., 2012; Pardoll, 2012). Importantly, these PD-1
pathway inhibitors demonstrated the greatest anti-tumor activity of any
immunotherapeutic approach tested in the clinic for the past 30 years. Several
antibodies targeting PD-1 and/or PD-L1 are currently in the clinical trial pipeline
(ClinicalTrials.gov). Recently, Keytruda (pembrolizumab: Merck) became the first PD-1
inhibitor to be approved by the FDA for use in patients with advanced melanoma
(FDA.gov).

1.6: The Lymphocytic Choriomeningitis Virus Model
The lymphocytic choriomeningitis virus, or LCMV, model of infection has been
invaluable in the research community as a tool to study viral persistence, host-pathogen
interactions, and anti-viral immunology. LCMV is an enveloped, ambisense RNA virus in
the Arenaviridae family. The natural reservoir of LCMV is the common mouse, Mus
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musculus. However, LCMV can cause disease in humans who are exposed to an
infected rodent (Zhou et al., 2012; De La Torre, 2009). LCMV enters cells via binding of
the GP-1 protein to its receptor, α-dystroglycan (Cao et al., 1998; Kunz, 2009). Due to
the broad tissue expression of α-dystroglycan, LCMV can infect multiple cell types and,
as a result, causes a systemic infection in mice. Despite widespread tissue distribution,
LCMV is a non-cytopathic virus, which means that in naturally-infected mice there is
minimal or no pathology associated with infection. In contrast, during experimental
infection with LCMV strains, pathology is strictly immune-mediated (Zhou et al., 2012;
Frebel et al., 2012; Borrow and Oldstone, 1999; Oldstone, 2006). There are multiple
strains of LCMV that cause distinct courses of infection in mice. Here, the primary strains
of interest are LCMV Armstrong (Arm), which causes an acutely-resolved infection in
mice, and LCMV clone 13, which causes a systemic, chronic infection in mice
(Matloubian and Ahmed, 2003; Ahmed et al., 1984; Dutko and Oldstone, 2011).
Importantly, CD8+ T cell anti-viral activity is critical for the control of both of these strains
of LCMV. For example, loss of IFN-γ or perforin results in lack of viral clearance and/or
control during LCMV infection (Walsh et al., 1994; Dorman et al., 1999; Bartholdy et al.,
2000). Dominant epitopes of LCMV that are recognized by CD8+ T cells are conserved
between LCMV Armstrong and clone 13, allowing for analysis of CD8+ T cells with the
same TCR specificity in these two different infection scenarios (Matloubian et al., 1990;
Butz and Bevan, 1998; van der Most et al., 1998). Thus, LCMV infection of mice is an
ideal model for the investigation of anti-viral CD8+ T cell responses.
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1.6.1: LCMV Strains: Armstrong and clone 13
Infection with LCMV Arm causes an acutely-resolved infection in
immunocompetent mice, with viral replication in the spleen, liver and kidney for
approximately 10 days. Clearance of virus is associated with a potent anti-viral CD8+ T
cell response that generates robust T cell memory (Salvato et al., 1988; Wherry et al.,
2003a; Dutko and Oldstone, 2011). A variant of LCMV Arm, known as LCMV clone 13,
leads to the establishment of a chronic infection in mice. LCMV clone 13 differs from
LCMV Arm by only 2 amino acid changes, a single change in the polymerase protein
and a single change in the GP-1 protein. Alterations in polymerase lead to enhanced
replication of LCMV in dendritic cells, as well as increased viral titers in macrophages
(Sevilla et al., 2000; Cao et al., 1998). In addition, the mutation in GP-1 results in higher
affinity binding of LCMV to α-dystroglycan, which causes increased early infection of
follicular dendritic cells and more severe destruction of lymphoid architecture (Mueller et
al., 2007; Matloubian et al., 1990; Borrow and Oldstone, 1995). Infection of mice with
LCMV clone 13 leads to systemic viral replication, with viremia lasting 2-3 months and
viral reservoirs persisting in many tissues for the life of the mouse (Oldstone, 2009;
Wherry et al., 2003a). CD8+ T cell responses to LCMV clone 13 become exhausted over
time and are also diminished in magnitude compared to LCMV Arm (Zajac and Ahmed,
1998; Gallimore and Zinkernagel, 1998). Loss of CD4+ T cell help leads to life-long
viremia during LCMV clone 13 and, as a result, more severe CD8+ T cell exhaustion
(Matloubian et al., 1994; Blackburn et al., 2009). Chapter 3 will utilize LCMV clone 13 as
a model of chronic viral infection.
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1.7: Influenza Virus Infection
Influenza A virus is a pathogen of significant human public health concern, as
thousands of deaths occur from influenza infection each year (CDC, 2013). Influenza A
belongs to the Orthomyxoviridae family and contains a negative-sense, segmented RNA
genome. Subtyping of influenza strains is determined by properties of the two major
influenza surface glycoproteins: haemagglutinin (HA) and neuraminadase (NA) (Bouvier
and Lowen, 2010). Both proteins play important roles in the binding of influenza to its
receptor, sialic acid, and entry into cells (Medina and García-Sastre, 2011; Mueller et al.,
2010). Mice are not a natural host of influenza; however, several strains have been
adapted by serial passage for use in mouse models. Intranasal infection of mice leads to
infection of epithelial cells in the bronchi and alveoli. As influenza is a cytopathic virus,
infection of epithelial cells leads to severe lung damage and pneumonitis (Rutigliano et
al., 2014; Askovich et al., 2013; Bouvier and Lowen, 2010). Pathogenesis in mice can be
monitored by weight loss, decreased blood oxygen saturation and, ultimately, survival
(Blazejewska et al., 2011; Laidlaw et al., 2013; Askovich et al., 2013). Studies have
shown that many arms of the immune response, including CD8+ T cells, CD4+ T cells, B
cells, and NK cells, are important for viral clearance during primary infection, as well as
for protection against secondary infection (Laidlaw et al., 2013). The focus of these
studies is on CD8+ T cell responses to influenza infection. Following infection of lung
epithelial cells, respiratory dendritic cells (DCs) carrying viral antigen drain to the
mediastinal lymph node where CD8+ T cell priming occurs (Kim and Braciale, 2009;
Yoon et al., 2007). Some CD8+ T cell priming also likely occurs in the spleen, mediated
by DCs migrating from the lungs. Activated CD8+ T cells then migrate back to the
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infected lung where lung-resident DC populations sustain effector T cell responses that
mediate viral clearance (McGill et al., 2008; Kim and Braciale, 2009).

1.7.1: Influenza Virus Mouse Model Strains: PR8 and X31
While many mouse adapted strains of influenza virus exist, these studies focus on
the viruses PR8 and X31. PR8 (A/Puerto Rico/8/1934) is an H1N1 virus that was
originally derived from a human influenza isolate. X31, in contrast, is an H3N2 virus with
6 of the internal genes of PR8 and the HA and NA genes derived from A/Aichi/2/1968
(Bouvier and Lowen, 2010; Medina and García-Sastre, 2011; Mueller et al., 2010).
Intranasal infection with X31 virus leads to approximately 20-25% weight loss by day 45; however, all mice will recover and survive the infection. In contrast, PR8 infection
typically leads to death of mice by day 5-6 post-infection. Consistent with these disease
outcomes, PR8 virus infection was shown to result in 4x higher viral load in the lungs of
mice at 18 hours post-infection compared to X31 virus infection (Askovich et al., 2013;
Bouvier and Lowen, 2010; Laidlaw et al., 2013). In the following studies, recombinant
PR8 and X31 viruses were utilized that contain the GP33-41 epitope of LCMV within the
NA stalk region. These recombinant influenza viruses induce robust GP33-specific CD8+
T cell responses in mice (Mueller et al., 2010).
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CHAPTER 2: PD-1 regulates the development and function of
memory CD8+ T cells following respiratory viral infection
Equal contribution by Jernej Godec and Arlene Sharpe, Ph.D.

2.1: Introduction
The development of functional effector and memory CD8+ T cells following acute
infection or vaccination requires the coordinated integration of key signals from antigenTCR (signal 1), co-stimulation (signal 2) and inflammation (signal 3) (Curtsinger et al.,
1999; Smith-Garvin et al., 2009; Acuto and Michel, 2003). The quantity and quality of
signals 1, 2, and 3 can impact CD8+ T cell activation and the subsequent development
of memory, but exactly how such signals regulate memory CD8+ T cell differentiation is
unclear (Iezzi et al., 1998; Tubo et al., 2013; Obar and Lefrançois, 2010). In particular,
signal 2 from co-stimulatory and/or co-inhibitory pathways has come under intense focus
given the recent application of antibodies blocking co-inhibitory receptors, such as PD-1,
for the treatment of cancer and chronic infections (Pardoll, 2012). Disrupting the PD1:PD-L pathway during chronic infections and cancer can enhance T cell activity and
improve outcomes (Barber et al., 2006; Topalian et al., 2012; Okazaki et al., 2013). In
addition, clinical trials with monoclonal antibodies targeting this pathway have shown
impressive 30–50% response rates in melanoma and multiple other cancers, including
renal cell and non-small cell lung carcinoma (Brahmer et al., 2012; Topalian et al.,
2012). Despite the clinical promise of PD-1 pathway blockade, how this pathway
regulates the formation and/or differentiation of CD8+ T cell memory remains poorly
understood.
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In contrast to the well-established role for PD-1 inhibitory functions in mediating T
cell exhaustion, there are conflicting data about the role of the PD-1 pathway in
controlling effector and memory CD8+ T cell differentiation during the acute phase of
infection. Lack of PD-1:PD-L signals during primary infection with rapidly disseminating
strains of LCMV results in lethal T cell-mediated immunopathology during the first week
of infection, consistent with an inhibitory role for this pathway during acute infection
(Frebel et al., 2012; Barber et al., 2006). Absence of PD-1 signals was also reported to
enhance the establishment of CD8+ T cell memory and/or skew T cells toward central
memory in some cases (Allie et al., 2011). In addition, the secondary expansion of
unhelped memory CD8+ T cells during acute re-challenge could be improved by the
blockade of PD-1:PD-L signals (Fuse et al., 2009). Other studies, in contrast, have
reported that loss or blockade of the PD-1 pathway during acute infection can diminish T
cell responses, suggesting a positive role for PD-1:PD-L interactions in other settings
(Rowe and Sing Way, 2008; Talay et al., 2009; Yao et al., 2009). The reasons for these
discrepancies and the precise role of the PD-1 pathway in the development of effector
and memory CD8+ T cells following acute infections, therefore, remains incompletely
understood.
One setting where the PD-1:PD-L pathway may be particularly important is in the
respiratory tract. During virulent LCMV infection in PD-1 KO mice, damage to the
pulmonary endothelium ultimately causes respiratory failure and contributes to mortality
(Frebel et al., 2012). In addition, while human anti-PD-1 cancer immunotherapy has
been generally well tolerated, several incidents of pneumonitis have raised concerns
about respiratory complications of PD-1 blockade (Brahmer et al., 2012; Topalian et al.,
2012). In mouse models of respiratory infections, PD-1:PD-L signals also have been
implicated in regulating immune responses. PD-1 expression is upregulated on
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responding CD8+ T cells during highly pathogenic influenza virus infection in mice and
during human metapneumovirus (HMPV) infection. Furthermore, increased PD-L1 and
PD-L2 expression in the respiratory tract during infection and inflammation may enhance
signals through this pathway (Erickson et al., 2012; Keir et al., 2008). Thus, in the
respiratory tract, PD-1:PD-L interactions have the potential to inhibit CD8+ T cell
function, which may limit pulmonary tissue damage, but could also impair optimal
pathogen control (Erickson et al., 2012). A better understanding of the consequences of
PD-1 signals during acute respiratory infections is needed to determine how PD-1
controls the balance between the generation of protective immunity and
immunopathology.
To address these issues we interrogated the role of the PD-1 pathway in effector
and memory CD8+ T cell differentiation during influenza virus infection in the respiratory
tract. Specifically, we investigated how disruption of PD-1:PD-L interactions impacted
the induction, stability, and longevity of effector and memory CD8+ T cells following
respiratory infection of mice lacking PD-1 (PD-1 KO) or both PD-L1 and PD-L2 (PDL1/L2 DKO). Lack of PD-1:PD-L signals led to a striking compromise in CD8+ T cell
memory, including reduced memory CD8+ T cell numbers and impaired secondary
responses. This defect in influenza-specific CD8+ T cell memory in PD-1 KO and PDL1/L2 DKO mice was associated with increased CD8+ T cell proliferation and expansion
early during infection, as well as increased contraction and loss of developing memory
CD8+ T cells during the effector to memory transition compared to WT mice. These
effects were cell intrinsic because PD-1 KO CD8+ T cells adoptively transferred to WT
mice had similar defects. These results are consistent with a role for PD-1:PD-L signals
in limiting CD8+ T cell activation during acute infection. However, these data also
indicate a crucial and previously unappreciated role for PD-1:PD-L signals in tempering
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the strength of initial activation to promote or “tune” optimal CD8+ T cell memory
formation. This tuning function of the PD-1 pathway during acute infection has
implications for clinical use of PD-1/PD-L1 blockade, including important effects on the
generation of CD8+ T cell memory following PD-1 cancer immunotherapy. This novel
tuning function also suggests that it may be possible to exploit the PD-1:PD-L pathway
to optimize immune memory following acute infection or vaccination

2.2: Methods
2.2.1: Mouse Strains
Wild-type C57BL/6 mice were purchased from The Jackson Laboratory (Bar
Harbor, ME). C57BL/6 mice lacking PD-1 (PD-1 KO) or both PD-1 ligands, PD-L1 and
PD-L2 (PD-L1/L2 DKO), have been described previously (Keir et al., 2007a, 2006). PD-1
KO P14 mice were generated by crossing germline PD-1 KO mice to P14 TCR
transgenic mice (Pircher et al., 1989). PD-1 KO (Ly5.2+ or Ly5.2+Ly5.1+) and WT
(Ly5.2+Ly5.1+ or Ly5.2+) P14 cells were isolated from peripheral blood and transferred
i.v into C57BL/6 recipient mice at a 1:1 ratio (500 WT P14 cells:500 KO P14 cells). All
mice were maintained in a pathogen-free facility and used according to institutional and
National Institutes of Health guidelines. Harvard Medical School and the University of
Pennsylvania School of Medicine are accredited by the American Association of
Accreditation of Laboratory Animal Care.

2.2.2: Viral Infection
For primary infection, 6 to 12 week old mice were infected with recombinant
influenza virus expressing the LCMV GP33-41 peptide (X31-GP33; 1.6x105 TCID50)
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intranasally (i.n.). For re-challenge infection, mice were infected with PR8-GP33 (10LD50
i.n) at least 35 days after primary infection. Recombinant influenza strains containing the
LCMV GP33-41 epitope inserted into the neuraminidase protein stalk region were provided
by Dr. Richard Webby (St. Jude Children’s Research Hospital, Memphis, TN) (Decman
et al., 2010; Mueller et al., 2010). These recombinant influenza strains replicate and
exhibit pathogenicity similar to their non-recombinant counterparts. Prior to infections,
mice were anesthetized by intraperitoneal (i.p.) injection of 2.5% Avertin (Sigma-Aldrich).
Viral titers in lungs were determined by quantitative real-time PCR as described (Laidlaw
et al., 2013).

2.2.3: Isolation of Cells from Tissues
Mouse lungs were mechanically disrupted in a GentleMACS Tissue Dissociator
(Miltenyi Biotech) and incubated with 2 mg/ml collagenase D (Worthington Biochemical
Corp.), and 3 µg/ml DNase I (Sigma) at 37°C for 30 min. Red blood cells (RBCs) were
lysed using ACK lysis buffer (Lonza). The resulting single cell suspensions were filtered
through a 70 mM cell strainer (BD Falcon). Spleen and lymph nodes were homogenized
using a cell strainer and RBCs lysed with ACK lysing buffer. Single cell suspensions
were stained, fixed with 2% paraformaldehyde (Electron Microscopy Sciences) and
analyzed on an LSR II (BD Biosciences). For intracellular cytokine staining (IFN-γ and
TNF-α), samples were stimulated with 0.5 µg/ml influenza A NP366-374 peptide or GP33-41
peptide (both Genscript) or no peptide for 5 hours at 37°C in the presence of GolgiPlug
(BD Biosciences), and then surface stained, fixed/permeabilized, and intracellularly
stained using the Cytofix/Cytoperm kit (BD Biosciences), as directed by the
manufacturer. For live/dead dye analysis, samples were washed in PBS (Gibco) and
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stained with Live/Dead green fluorescent reactive dye (Invitrogen) in PBS at room
temperature for 15 minutes, washed twice with PBS and then surface stained for
analysis.

2.2.4: Antibodies, Tetramers, and Flow Cytometry
Antibodies to CD8 (53-6.7), CD44 (IM7), IFN-γ (XMG1.2), TNF-α (MP6-XT22),
CD127 (SB/199), CD122 (TM-b1), CD62L (MEL-14) CD45.1 (A20), CD45.2 (104),
CD103 (2E7) were purchased from Biolegend. Antibody to Ki-67 was purchased from
BD Biosciences. The KLRG1 mAb (2F1) was purchased from Abcam. Poly-caspase
analysis was performed with Flica Vybrant FAM Poly Caspases Assay Kit (Life
Technologies). Dead cell exclusion was performed by live/dead fluorescent reactive dye
(Invitrogen) staining. Tetramers for GP33-41, NP366-374, and PA224-233 were prepared and
used as described (Laidlaw et al., 2013). Flow cytometry data were acquired on BD LSR
II flow cytometer and analyzed using FlowJo software (Tree Star).

2.2.5: BrdU Treatment and Detection
Animals were treated with 2mg of BrdU (Sigma-Aldrich) i.p. at the indicated time
prior to tissue harvest and analysis. BrdU incorporation was assessed by the BrdU Flow
Kit per manufacturer’s instructions (BD Biosciences).

2.2.6: Statistical Analysis
Data were analyzed using Student’s t-test for normally distributed data and p
values <0.05 were considered significant.
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2.3: Results
2.3.1: Virus-specific CD8+ T cell memory development is impaired in mice
lacking PD-1 signals
To investigate the impact of PD-1 pathway deficiency on CD8+ T cell memory
development following acute respiratory viral infection, we infected WT, PD-1 KO or PDL1/L2 DKO mice with influenza virus X31-GP33 (H3N2) and examined virus-specific
CD8+ T cells 60-85 days later (Figure 2.1A). The frequency and total number of virusspecific memory CD8+ T cells were reduced in the lungs of PD-L1/L2 DKO (Figure 2.1B)
and PD-1 KO mice (Figure 2.1C). While true for all responses examined, the magnitude
of the difference was greater for subdominant CD8+ T cell responses (PA224-specific and
GP33-specific) than for immunodominant NP366-specific responses (Figure 2.1B and
2.1C). A similar decrease in CD8+ T cell responses was observed in the spleen,
mediastinal (lung-draining) lymph node (dLN), and bone marrow (data not shown). While
the expression of KLRG1, CD127 (IL-7R), CD103, and CD69 was similar between WT
and PD-L1/L2 DKO mice (Figure 2.2A), fewer memory CD8+ T cells from the DKO mice
produced IFN-γ and TNF-α upon ex vivo re-stimulation with influenza peptides (Figure
2.2B).
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Figure 2.1: Magnitude of CD8+ T cell memory response is impaired in PD-1
pathway-deficient mice. (A) Schematic of experimental design. (B) Representative
plots (left) show the frequency of H-2Db PA224+ CD8+ T cells in the lungs of WT or PDL1/L2 DKO mice on d60+ p.i. with X31-GP33. Numbers indicate percent CD8+ T cells
positive for PA224+ tetramer. Summary of frequencies of CD8+ T cells specific for other
influenza epitopes is shown to the right. (C) Representative plots (left) show the
frequency of H-2Db PA224+ CD8+ T cells in the lungs of WT or PD-1 KO mice on d60+
p.i. with X31-GP33. Numbers indicate percent CD8+ T cells positive for PA224+
tetramer. Summary of frequencies of CD8+ T cells specific for other influenza epitopes is
shown to the right.
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A hallmark property of memory T cells is the ability to mount robust secondary
responses upon re-infection. Recent studies suggest that disruption of PD-1:PD-L
interactions during secondary challenge may improve CD8+ T cell recall responses
(Erickson et al., 2012, 2014). However, it is unclear whether PD-1:PD-L interactions
during primary viral infection promote or limit the formation of memory CD8+ T cell
populations capable of mounting potent secondary responses. To test the ability of
memory CD8+ T cells that developed without the PD-1:PD-L pathway to mount
secondary responses, we re-challenged X31-GP33 immune WT, PD-1 KO and PDL1/L2 DKO mice with the heterotypic H1N1 strain of influenza virus, PR8-GP33. Since
neutralizing antibodies do not cross-react between these viruses, memory CD8+ T cells
play a central role in recall responses and protective immunity in this setting (Flynn et al.,
1998; Mueller et al., 2010). PD-1 KO and PD-L1/L2 DKO mice had significantly
increased viral titers in the lung compared to WT mice 3.5 days (d3.5) following rechallenge (Figure 2.3A). This defect in viral control was accompanied by more severe
weight loss in PD-1 KO and PD-L1/L2 DKO mice, while WT mice showed minimal
morbidity (Figure 2.3B). Failure to efficiently control re-challenge in PD-1 KO and PDL1/L2 DKO mice was associated with lower frequencies and absolute numbers of
influenza-specific CD8+ T cells in the lung at d3.5 post re-challenge (Figure 2.3C and
data not shown). Furthermore, fewer CD8+ T cells from PD-L1/L2 DKO mice produced
cytokines upon influenza peptide stimulation at d3.5 post re-challenge (Figure 2.3D). By
d7 post re-challenge, however, the frequencies and numbers of virus-specific CD8+ T
cells in the lungs were comparable in WT and PD-L1/L2 DKO mice and virus was
cleared (data not shown). Thus, the defect in memory CD8+ T cell responses in PDL1/L2 DKO mice manifests as a delay in the kinetics of viral clearance. This change in
protective immunity is associated with reduced ability to mount a robust influenza-
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specific secondary CD8+ T cell response. Taken together, these data indicate a key role
for the PD-1 pathway in regulating the development of optimally functional CD8+ T cell
memory.

Figure 2.3
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Figure 2.3: Defective recall capacity of memory CD8+ T cells in PD-1 pathway
deficient mice. (A) Influenza viral titers in the lung at d3.5 p.i. and longitudinal weight
loss (B) in X31-GP33 immune WT and PD-L1/L2 DKO mice following re-challenge with
PR8-GP33. (C) Frequencies of indicated tetramer+ CD8+ T cells in lungs of X31-GP33
immune WT and PD-L1/L2 DKO mice at d3.5 following re-challenge. (D) Representative
plots of intracellular cytokine staining (ICS) for IFN-γ and TNF-α production in lung CD8+
T cells from (D) stimulated ex vivo with NP366. Fraction of responding cells summarized
to the right. Data are representative of 3-5 independent experiments with 4-5 mice per
experiment.
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2.3.2: The PD-1 pathway regulates the memory CD8+ T cell compartment
by controlling initial CD8+ T cell expansion and contraction.
Given the ability of PD-1 to modulate T cell activation, we hypothesized that
alterations in CD8+ T cell memory may stem from early changes in T cell priming and
effector differentiation. To test this possibility, we compared influenza-specific CD8+ T
cell responses at the height of the primary response, d8-10 post-infection, in WT and
PD-L1/L2 DKO mice infected with X31-GP33 virus. While all mice had similar
frequencies of influenza-specific effector CD8+ T cells in the lung (Figure 2.4A), there
was a significant increase in the total number of CD8+ T cells in PD-L1/L2 DKO mice,
consistent with a negative regulatory role for this pathway (Figure 2.4B). However, this
enhanced expansion of CD8+ T cells in PD-L1/L2 DKO mice was associated with a
subsequent decrease in the frequency of influenza-specific CD8+ T cells in these mice
during the contraction phase, d15-20 p.i. (data not shown). While there was no
significant difference in total numbers at d15-20 (data not shown), the ratio of DKO:WT
virus-specific CD8+ T cells began to dramatically decline after d10 p.i. (Figure 2.4C). Of
note, the immunodominant NP366-specific CD8+ T cell responses displayed slower
kinetics in this deterioration (Figure 2.4C). Thus, while PD-1 pathway deficiency led to
an initial increase in virus-specific CD8+ T cells, there was an erosion of virus-specific
CD8+ T cell responses in PD-L1/L2 DKO mice during the establishment of
immunological memory. Analysis of CD8+ T cell functionality at d10 p.i. revealed no
significant differences in the frequency of cytokine-producing cells in the lungs of WT,
PD-1 KO or PD-L1/L2 DKO mice or the quality of the cytokine response on a per cell
basis (Figure 2.4D), suggesting that the major effect of removing PD-1 signals was
enhanced numerical expansion. These findings suggest that PD-1 negatively regulates
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CD8+ T cell effector differentiation predominantly by limiting overall CD8+ T cell
expansion. Furthermore, these data also suggest suboptimal transition to memory
without PD-1 or PD-L1/L2 signals.

Figure 2.4
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Figure 2.4: Altered effector CD8+ T cell expansion and contraction in the absence
of PD-1 pathway signals. (A, B) Frequencies (A) and numbers (B) of indicated
tetramer+ CD8+ T cells in the lungs of WT and PD-L1/L2 DKO mice at d10 after primary
X31-GP33 infection. (C) Ratios of numbers of influenza-specific CD8+ T cells in PDL1/L2 DKO vs. WT mice over time after primary X31-GP33 infection. (D) Representative
plots of intracellular cytokine staining for IFN-γ and TNF-α production in lung CD8+ T
cells following ex vivo stimulation with NP366. Representative plots gated on CD8+
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CD44+ T cells (left) and summary of fraction of percent responding cells (right) from 5
mice per group.

2.3.3: Increased turnover of CD8+ T cells in the absence of PD-1 signaling.
To better understand the differences in effector and memory CD8+ T cell
development in the absence of PD-1 signals, we performed transcriptional profiling of
influenza-specific CD8+ T cells from the lungs of WT and PD-L1/L2 DKO mice at d8 p.i.
We focused these analyses on subdominant (PA244 and GP33) influenza-specific CD8+
T cells, since profound phenotypic and functional differences were observed in these
populations at d8 p.i. Gene set enrichment analysis (GSEA) using Gene Ontology (GO)
was used to elucidate pathways and biological processes uniquely regulated in the
absence of PD-1 signals. Most of the significantly enriched pathways (p<0.001,
FDR<0.001) were related to cell division (Figure 2.5A). We further analyzed three
representative pathways enriched in the WT cells – mitosis, spindle assembly, and DNA
replication (Figure 2.5B). Among those genes highly over-expressed in WT relative to
PD-L1/L2 DKO CD8+ T cells, the majority were members of one or more of these
enriched pathways (Figure 2.5C). These data suggest a direct link between PD-1:PD-L
signals and control of cell cycle during early activation and proliferation of virus-specific
CD8+ T cells during influenza infection.
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Figure 2.5: Altered expression of genes representing cell division pathways in WT
versus PD-L1/L2 DKO virus-specific CD8+ T cells. (A) Top and bottom 250
differentially expressed genes in subdominant-epitope specific WT and DKO CD8+ T
cells ranked by signal-to-noise values following filtration to top 10% of genes with
highest mean absolute deviation across samples. Membership of genes in the three
representative GO terms is shown on the right. (B) Significantly enriched (FDR<0.01)
gene sets in WT CD8+ T cells clustered based on the extent of gene member overlap
and annotated for the biological states/processes they represent. (C) Representative GO
gene sets enriched in transcriptional profiles from virus-specific CD8+ T cells from the
WT versus PD-L1/L2 DKO mice. Gene expression microarray was performed to
compare subdominant influenza epitope-specific lung CD8+ T cells isolated from WT
and PD-L1/L2 DKO mice at d8 following primary X31-GP33 infection.
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Based on GSEA alone, it is challenging to determine whether enrichment of
replication and cell division pathways in CD8+ T cells from WT versus PD-L1/L2 DKO
mice reflects altered proliferation or if these gene expression changes could simply be
due to differences in the contraction of WT versus DKO CD8+ T cell responses. To
directly investigate the mechanism responsible for the quantitative differences in early
WT and PD-1 pathway deficient CD8+ T cell responses, we compared proliferation and
cell death of influenza-specific CD8+ T cells on d6-8 p.i. in the lung, spleen, and dLN of
WT and PD-L1/L2 DKO mice. At d8 p.i., more influenza-specific CD8+ T cells in the
spleens of PD-L1/L2 DKO mice expressed the cell cycle protein Ki-67 compared to WT
mice, suggesting increased proliferation in the absence of PD-1 signaling (Figure 2.6A).
These findings are consistent with the higher cell numbers observed in the lung of PDL1/L2 DKO mice at d10 p.i. (Figure 2.4B). However, significantly fewer virus-specific
CD8+ T cells were Ki-67+ in the lungs of PD-L1/L2 DKO mice (Figure 2.6A). These
findings suggest that the increased number of CD8+ T cells in the lungs of PD-1 KO and
PD-L1/L2 DKO mice at the early stages of infection is largely due to robust proliferation
in lymphoid organs and homing/trafficking of these CD8+ T cells to the lung.
Interestingly, PD-L1/L2 DKO mice had a higher frequency of influenza-specific CD8+ T
cells that were positive for active caspase staining (FLICA) in the lung, but not in the
spleen on day 8 p.i. (Figure 2.6B and data not shown) compared to WT mice,
consistent with the increased contraction of the DKO populations. This increase in
apoptosis of PD-L1/L2 was further confirmed by Annexin V staining in the lung (data not
shown). Thus, the PD-1 pathway plays an important role in tempering early CD8+ T cell
proliferation in lymphoid tissues, which is critical for CD8+ T cell survival at the site of
infection and subsequent memory formation.
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Figure 2.6: CD8+ T cells undergo robust proliferation but have reduced survival in
the absence of PD-1 signaling in influenza-infected mice. (A) Flow cytometric
analysis of Ki-67 expression by NP366-specific CD8+ T cells from WT and PD-L1/L2
DKO mice at d8 p.i. in the spleen (top) and lung (bottom). Numbers indicate fraction of
Ki-67-expressing influenza-specific CD8+ T cells. Representative plots shown to the left.
Summary of Ki-67+ cells shown for indicated tetramers to the right. (B) Flow cytometric
analysis of active caspase by FLICA staining of NP366-specific CD8+ T cells from WT
and PD-L1/L2 DKO mice at d8 p.i. in the lung. Numbers indicate fraction of influenzaspecific T cells positive for FLICA staining based on unstained controls. Representative
plots shown on the left and summary of FLICA+ cells shown for indicated tetramers to
the right.
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Figure 2.6

2.3.4: The regulation of CD8+ T cell memory differentiation by PD-1 is cellintrinsic.
One possible reason for altered proliferation and survival dynamics of the effector
CD8+ T cell responses in PD-1 pathway deficient mice is that these mice clear a primary
influenza infection faster than WT mice. Such an accelerated clearance of primary
infection could result in truncated exposure of T cells to the optimal levels of antigen and
inflammation needed for proper memory development. Indeed, PD-1 pathway deficient
mice cleared influenza virus more rapidly than WT mice and had significantly decreased
viral titers in the lungs on d3.5 after primary infection (Figure 2.7A). Enhanced control of
infection was associated with reduced weight loss and faster recovery of PD-1 pathway
deficient mice (Figure 2.7B). These observations suggest that early viral clearance may
contribute to altered CD8+ T cell responses in PD-1 KO and PD-L1/L2 DKO mice. Thus,
defective T cell memory in the absence of PD-1 signals could be due to accelerated
control of infection and/or differences in T cell differentiation when cell-intrinsic PD-1
signals are absent.
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Figure 2.7
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Figure 2.7: WT mice clear primary influenza infection more quickly than PD-1
pathway deficient mice. (A) Influenza viral titers in the lung at d3.5 p.i. and longitudinal
weight loss (B) in WT and PD-L1/L2 DKO mice following primary infection with X31GP33.
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To directly test whether PD-1 signals had a cell-intrinsic role in regulating CD8+ T
cell memory differentiation during influenza infection, we co-transferred equal numbers
of WT and PD-1 KO P14 TCR transgenic CD8+ T cells (recognizing GP33-41 peptide
presented by H-2Db) into WT mice followed by infection with X31-GP33 virus (Figure
2.8A). This approach allows for direct comparison of WT and PD-1 deficient CD8+ T
cells in the same mice and excludes differences in precursor frequency, TCR repertoire,
viral control, effects of PD-L1 and/or PD-L2 on APCs or influenza pathogenesis.
Consistent with findings in PD-1 KO and PD-L1/L2 DKO mice, the frequency (Figure
2.8B) and total numbers (Figure 2.8C) of PD-1 KO P14 cells were significantly higher
than WT P14 cells in the lung and spleen at d7 p.i., with similar trends in the blood and
dLN. The increased frequency of PD-1 KO P14 cells was associated with increased
BrdU incorporation in the spleen and dLN (Figure 2.9A) and increased Ki-67 expression
in the spleen (data not shown), indicating that PD-1 regulates CD8+ T cell proliferation in
a cell-intrinsic manner. Similar to virus-specific T cells in influenza-infected PD-1 and
PD-L1/L2 DKO mice, PD-1 KO P14 cells and WT P14 cells incorporated BrdU to a
similar extent in the lung at d7 p.i. (Figure 2.9A). However, PD-1 KO P14 cells were
more prone to cell death, as demonstrated by increased FLICA staining and surface
Annexin V at d10 p.i. (Figure 2.9B and data not shown).
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Figure 2.8
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Figure 2.8: PD-1 controls the magnitude of the CD8+ T cell response in a cellintrinsic manner. (A) Schematic of experimental design utilizing TCR transgenic P14
transfer (B) Representative plots (left) show the frequency of WT and PD-1 KO P14 cells
in indicated organs at d7 p.i. with X31-GP33. Numbers indicate frequency of P14 cells
as a percent of CD8+ T cells. Summary of frequencies of P14 cells is shown to the right.
(C) Summary of absolute numbers of WT and PD-1 KO P14 cells at d7 p.i. with X31GP33 in the spleen.
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Figure 2.9
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Figure 2.9: PD-1 regulates CD8+ T cell proliferation and cell death in a cell-intrinsic
manner. (A) Flow cytometric analysis of BrdU incorporation by WT and PD-1 KO P14
cells in the spleen at d7 p.i. Numbers indicate fraction of BrdU+ P14 cells.
Representative plots shown to the left. Summary of BrdU+ P14 cells in different organs
shown to the right. (B) Flow cytometric analysis of active caspase by FLICA staining of
WT and PD-1 KO P14 T cells on d8 p.i. in the lung. Numbers indicate fraction of P14
cells positive for FLICA staining based on unstained controls. Representative plot shown
to the left. Summary of FLICA+ cells shown to the right.
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We used the P14 co-transfer system to interrogate whether these early cellintrinsic alterations in proliferation and cell death also resulted in aberrant memory
development. We assessed the number, phenotype and functionality of WT and PD-1
KO P14 cells 35-100 days p.i. While WT P14 cells formed stable memory, PD-1 KO P14
cells underwent progressive contraction and were less abundant than WT P14 cells in
the lung and spleen after 3 months (Figure 2.10A), consistent with the memory attrition
observed in the whole animal KO experiments described above. Although no differences
in the differentiation state were observed based on expression of key memory markers
(data not shown), significantly fewer PD-1 KO memory P14 cells from the lung or spleen
were capable of producing IFN-γ and TNF-α upon re-stimulation compared to WT cells
(Figure 2.10B). To test whether memory recall capacity was compromised as a result of
cell-intrinsic deficiency in PD-1 signals, influenza X31-GP33 immune mice containing
WT and PD-1 KO P14 cells were re-challenged with PR8-GP33. Following re-challenge,
PD-1 KO P14 memory cells displayed dramatically impaired secondary expansion
compared to WT P14 cells in the same animals (Figure 2.10C). These results point to a
key function for PD-1 signals in regulating T cell proliferation and survival during the
acute phase of infection and indicate that the proper regulation of these events during T
cell priming and expansion has a major impact on subsequent CD8+ T cell memory.
Collectively, these data indicate that PD-1 regulates the differentiation and establishment
of CD8+ T cell memory in a cell-intrinsic manner.
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Figure 2.10
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Figure 2.10: Cell-intrinsic defect in CD8+ T cell memory in the absence of PD-1. (A)
Summary of WT and PD-1 KO P14 absolute cell numbers in the lung and spleen during
primary X31-GP33 infection. (B) Representative plots of intracellular cytokine staining for
IFN-γ and TNF-α production in WT and PD-1 P14 cells from spleen and lung (left) and
summary data (right). (C) Representative plots of WT and PD-1 KO P14 cell
percentages 35 days after primary infection with X31-GP33 (d35) and 7 days post rechallenge with PR8-GP33 (d42 after primary infection). Summary of fold change of
numbers of P14 cells pre- and post- re-challenge shown to the right.
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Figure 2.11
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Figure 2.11: Model of the role for PD-1 signals in effector and memory CD8+ T cell
responses to influenza virus infection. In WT mice (left), PD-1 pathway signals early
during influenza virus infection restrict early activation and proliferation of virus-specific
CD8+ T cells in dLNs. These T cells then migrate into the infected lung, where inhibition
by the PD-1 pathway promotes their survival and continued proliferation, allowing for
clearance of influenza virus and the development of optimally-functional memory CD8+ T
cells. In settings of PD-1 pathway deficiency (right), virus-specific CD8+ T cells undergo
excessive proliferation in dLNs and migrate to the lungs in high numbers. While this
leads to faster clearance of primary influenza infection, virus-specific CD8+ T cells
undergo increased apoptosis in the lung and, ultimately, develop into poorly functional
and unstable memory cells.
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2.4: Discussion
The PD-1 pathway has a key role in regulating T cell responses. This pathway
has become an important immunotherapeutic target in cancer and has promise for the
treatment of chronic infections. The rapid up-regulation of the PD-1 pathway during the
effector phase of immune responses suggests that PD-1:PD-L signals also exert
important immunoregulatory functions during effector and memory responses following
acute infection or vaccination. However, the role of PD-1 signals in this context is poorly
understood. Here we have investigated how the PD-1 pathway regulates the generation
and maintenance of CD8+ T cell memory. We found that PD-1 KO and PD-L1/L2 DKO
mice developed suboptimal memory CD8+ T cells that lack long-term stability and
protect poorly against secondary re-challenge. This defect in memory was associated
with early excessive proliferation of effector CD8+ T cells, coupled with increased cell
death. Ultimately, without PD-1 signals, virus-specific CD8+ T cells lose or never
develop the robust recall capacity and secondary proliferation that is characteristic of
memory T cells. Taken together, our work reveals an important role for the PD-1
pathway in the optimal development of long-lived memory responses by acting to tune
the strength of stimulation and temper early proliferation of CD8+ T cells (Figure 2.11).
During acute respiratory infections, the PD-1:PD-L pathway might have a
particularly important role in controlling the balance between immunopathology and
effective anti-pathogen immunity and memory development. For example, virulent LCMV
infection in PD-1 KO mice leads to damage of the pulmonary endothelium that ultimately
causes respiratory failure and contributes to mortality (Frebel et al., 2012). These studies
suggest that PD-1 restricts T cell responses to acute stimulation in the lung, likely to
prevent excessive immune-mediated damage. Studies of pathogenic respiratory
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infections also suggest a role for PD-1:PD-L1 signals in limiting immunopathology
(Erickson et al., 2012). Our findings now reveal that another key function of this negative
regulation by PD-1 during acute stimulation is to moderate excessive T cell stimulation
and thereby facilitate the development of optimal CD8+ T cell memory.
Several groups have demonstrated the potent ability of PD-1 to inhibit TCR and
co-stimulatory signals, implicating the PD-1 pathway in effector and memory T cell
responses (Butte et al., 2007; Freeman et al., 2000a; Parry and Riley, 2005; Yokosuka
et al., 2012). However, there are conflicting data about how PD-1:PD-L signals impact
effector and memory T cell responses during acute infection. In the respiratory tract, for
example, antibody blockade of PD-L1 during human metapneumovirus (HMPV) and or
genetic deletion of PD-1 during influenza virus infection enhanced CD8+ T cell
functionality early in the immune response, consistent with our findings (Erickson et al.,
2012, 2014). In addition, blockade of PD-L1 just prior to HMPV re-challenge leads to a
more robust secondary CD8+ T cell response and enhanced viral clearance compared
to control treated mice. However, other reports demonstrate that the lack of PD-1:PD-L
signals can either enhance or inhibit primary effector CD8+ T cell responses following
acute infection, depending on the model (Allie et al., 2011; Fuse et al., 2009; Rowe and
Sing Way, 2008; Talay et al., 2009; Yao et al., 2009). While transient blockade of PD-1
signals can improve recall responses of memory CD8+ T cells, there is also evidence
that genetic absence of PD-1 can skew memory CD8+ T cell differentiation towards
either effector memory or central memory depending on the context. Thus, the precise
role of PD-1:PD-L signals in the formation of long-term immunity and T cell memory has
remained unclear.
Our results highlight the importance of PD-1 inhibitory signals in tempering initial
CD8+ T priming. While DCs are a prime candidate for the specific APC involved in these
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interactions, it is possible that PD-L1/L2 on other cell types could also negatively
regulate T cells. The inhibition by the PD-1 pathway in lymphoid tissues likely plays a
central role in early skewing of effector T cell differentiation. However, interactions
between CD8+ T cells with PD-L1/L2 on resident DCs, infected epithelial cells and/or
lung macrophage populations in the infected lung are also likely to be important. We find
that CD8+ T cells have decreased survival in the lung between d10-20 p.i. when PD-1
signaling is absent. Taken together, these findings suggest that PD-1-mediated restraint
during the early expansion of CD8+ T cells in draining lymphoid tissue is needed to
promote the generation and survival of developing effector and memory CD8+ T cells.
The ability of the PD-1 pathway to modulate effector and memory CD8+ T cell
differentiation makes it an attractive therapeutic target for infectious diseases and
cancer, as well as for augmenting vaccination strategies. Blocking PD-1 pathway signals
may prove beneficial in boosting early effector responses to promote pathogen or tumor
clearance. The long-term effects of PD-1 pathway blockade, however, may improve
memory T cell development in some settings, while preventing optimal memory
formation in others. Better understanding of how the PD-1 pathway regulates CD8+ T
cell responses in divergent settings of infectious disease and cancer will help inform how
to administer PD-1 or PD-L1 blocking antibodies to enhance memory T cell responses.
In order to most effectively target the PD-1 pathway to improve T cell memory
development, several key questions must be addressed. It is not yet clear when during
the course of infection it is most beneficial to block the PD-1 pathway. The timing of PD1 blockade appears to be key, and blockade at the time of initial CD8+ T cell priming
may have different consequences from blockade of pre-existing memory T cells during a
recall response. Indeed, our data suggest that very early removal of PD-1 signals during
primary infection can prevent optimal memory differentiation, while other data
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demonstrate that blockade of PD-1 just prior to re-challenge improves secondary
expansion of memory CD8+ T cells. It may be that targeting the PD-1 pathway during
different stages of infection (i.e. priming, expansion, contraction, or memory phase) will
result in distinct effects on CD8+ T cell differentiation, recall responses and/or memory
maintenance. The answers to these questions will be critical for determining how to best
modulate PD-1 to enhance responses to vaccines for infectious agents and cancer.
Additionally, while we have focused primarily on the CD8+ T cell-intrinsic role of PD-1 on
memory development, the PD-1 pathway regulates many other important cell types,
including CD4+ T cells, B cells, NK cells, and APCs. It will be interesting to investigate
how the loss of PD-1 pathway signals affects the behavior of these cell types during
infection with influenza virus and infections.
In summary, we have identified a key role for the PD-1 pathway in controlling
effector and memory CD8+ T cell differentiation during influenza virus infection. Negative
regulation by PD-1 and its ligands is needed to promote optimal formation of long-lived,
protective memory CD8+ T cells. Our studies implicate the PD-1 pathway as a prime
target for altering development of effector and memory CD8+ T cell responses during
therapeutic and vaccination strategies. We have identified control of cell cycle and
apoptosis as one mechanism by which PD-1:PD-L signals influence CD8+ T cell
memory. Future studies are needed to identify additional molecular pathways by which
PD-1:PD-L signals regulate CD8+ T cell differentiation in different disease settings, as
well as to further test the potential of combining PD-1 pathway manipulation with current
vaccine strategies.
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CHAPTER 3: Genetic Absence of PD-1 promotes accumulation
of terminally-differentiated exhausted CD8+ T cells during
chronic viral infection

3.1: Introduction
Chronic viral infections, such as HIV, HCV, and others, place a significant strain
on anti-viral T cell responses, forcing continued proliferation, cytokine production, and
killing of infected cells for months or years. As a result, anti-viral CD8+ T cell functions
become sub-optimal over time, a phenomenon known as T cell exhaustion (Shankar et
al., 2000; Zajac and Ahmed, 1998; Gallimore et al., 1998; Gruener et al., 2001a; Wherry,
2011). Two of the cardinal features of exhausted CD8+ T cells are the gradual loss of
effector capabilities and the sustained high expression of multiple inhibitory receptors.
Exhausted CD8+ T cells also have altered expression of key transcription factors,
including Tbet, Eomesodermin (Eomes), and Blimp-1 (Wherry, 2011; Wherry et al.,
2003a; Blackburn et al., 2009). Importantly, CD8+ T cell exhaustion contributes to failed
immune control during chronic infection and cancer.
The inhibitory receptor Programmed Death-1 (PD-1) is considered to be a central
regulator of CD8+ T cell exhaustion. Expression of PD-1 and its primary ligand, PD-L1,
is highly upregulated during chronic infection and cancer (Barber et al., 2006; Freeman
et al., 2006; Blank et al., 2005). The importance of this elevated PD-1 pathway
expression has been demonstrated in several animal models where in vivo antibodymediated blockade of PD-1 or PD-L1 re-invigorates exhausted CD8+ T cell responses
and decreases viral load or tumor burden (Barber et al., 2006). Recent clinical trials have
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extended these observations from mouse models to humans, demonstrating a potent
ability of PD-1 pathway blockade to revitalize anti-tumor immunity in late-stage cancer
patients (Brahmer et al., 2012; Topalian et al., 2012). The observations of reversibility of
exhaustion by PD-1 pathway blockade demonstrate that exhausted CD8+ T cells, or at
least a subset of the population, are not terminally dysfunctional. Furthermore, blockade
of various other inhibitory receptors alone and in combination with PD-1/PD-L1 blockade
suggests that PD-1 is the major inhibitory receptor controlling exhaustion (Blackburn and
Wherry, 2008; Blackburn et al., 2009; Kassu et al., 2010; Wherry et al., 2007). While it is
clear that PD-1 based therapies have exciting clinical potential and can dramatically
improve exhausted T cell responses, the precise role of PD-1 in exhausted CD8+ T cells
remains undefined.
A fundamental unresolved question is what role PD-1 signals play in initiating
and/or establishing the program of T cell exhaustion. One possibility is that PD-1 directly
causes the development of CD8+ T cell exhaustion. This question has previously been
challenging to address since PD-1 pathway deficiency results in excessive CD8+ T cellmediated immunopathology and altered viral pathogenesis, preventing analysis of T cell
responses after the first week post-infection (Barber et al., 2006; Frebel et al., 2012).
However, the robust functionality of CD8+ T cells in the absence of PD-1 at these early
time-points suggests that T cell exhaustion may not develop without PD-1 signals. This
outcome would implicate the PD-1 pathway as a major regulatory pathway inducing the
development of exhausted T cell populations. Alternatively, PD-1 could inhibit CD8+ T
cell function during chronic infection but may not play a direct role as the initiator of the
program of exhaustion. In this scenario, CD8+ T cells could still become exhausted even
in settings of PD-1 deficiency. The implications of these two distinct possibilities are
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important for the design and implementation of therapies blocking or manipulating the
PD-1 pathway in cancer, infections and other diseases.
Here we have used a dual adoptive transfer approach that allowed us to study
the development of PD-1 deficient (PD-1 KO) anti-viral CD8+ T cell responses during
chronic LCMV infection in the absence of lethal immune-mediated damage and altered
viral pathogenesis. Surprisingly, genetic deletion of PD-1 on virus-specific CD8+ T cells
was insufficient to prevent the development of exhaustion. In fact, PD-1 KO virusspecific CD8+ T cells were less functional and had higher expression of other inhibitory
receptors compared to WT virus-specific CD8+ T cells. Early over-stimulation and robust
proliferation in the absence of PD-1 led to disruption of a critical proliferative hierarchy
between T-bethi and Eomeshi subsets of exhausted CD8+ T cells that is necessary for
sustained responses during chronic infections (Paley et al., 2012). As a result, long-term
proliferation and stability of exhausted T cell responses was compromised without PD-1.
However, improved cytotoxic ability and increased localization of exhausted CD8+ T
cells to peripheral tissues without PD-1 suggests that the PD-1 pathway has previously
unappreciated roles in shaping exhausted CD8+ T cell populations. These findings
demonstrate that PD-1 signals do not instruct the development of CD8+ T cell
exhaustion. PD-1 is, however, required to prevent terminal-differentiation of exhausted
CD8+ T cells while simultaneously controlling important anatomical and functional
aspects of these cells. These findings have important implications for understanding the
long-term impact of PD-1 based therapies in humans.
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3.2: Methods
3.2.1: Mice and Infections
PD-1 deficient (PD-1 KO) mice were crossed to C57BL/6 P14 mice to generate
PD-1 KO P14 mice (Keir et al., 2007b; Pircher et al., 1989). Mice were infected with
either 2 x 105 PFU of lymphocytic choriomeningitis virus (LCMV) Armstrong strain by i.p.
injection to generate an acutely resolved infection or 4 x 106 PFU of LCMV clone 13
strain by i.v. injection to generate a chronic infection. In experiments with CD4 depletion,
200 mg of anti-CD4 antibody (GK1.5; BioXcell) was administered i.p. on d-1 and d1 of
LCMV infection. Viral titers were measured as previously described (Kao et al., 2011).
All animals were housed at the University of Pennsylvania (Philadelphia, PA).
Experiments were performed in accordance with protocols approved by the University of
Pennsylvania Institutional Animal Care and Use Committee.

3.2.2: Adoptive Transfer and Lymphocyte Isolation
CD8+ T cells were isolated from peripheral blood or spleens of naïve WT or PD-1
KO P14 mice. For spleen isolation, P14 cells were purified by CD8 negative selection
(Stem Cell Technologies). Depending on the experiment, the appropriate number of WT
or PD-1 KO cells was transferred into separate naïve recipient mice or mixed at a 1:1
ratio at indicated cell numbers and transferred into naïve recipient mice. For proliferation
assays, P14 cells were labeled with 10 mM CellTraceViolent (Life Technologies) before
transfer. For flow cytometry after infection, major organs were removed on indicated
days and single-cell suspensions were prepared as described.
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3.2.3: Flow Cytometry and Cell Sorting
All cells were stained with LIVE/DEAD® Fixable Dead Cell Stain (Life
Technologies) to discriminate live from dead cells. Surface staining was performed as
described previously (Kao et al., 2011). For intracellular cytokine staining, single-cell
suspensions were incubated for 5h at 37 °C with or without 1 µM gp33 peptide
(KAVYNFATM)

and

were

stained

with

a

Cytofix/Cytoperm

kit

according

to

manufacturer’s instructions (BD Biosciences). For intracellular staining of transcription
factors, a Foxp3 staining kit was used according to the manufacturer's instruction
(eBioscience). Antibodies used for flow cytometry were purchased from BD Biosciences
(CD4, CD8, CD19, CD44, 2B4, Ki67), Biolegend (PD-1 (RMPI-30 clone), Tim-3, TNFa,
IFNg, Tbet; San Diego, CA), R&D Systems (MIP-1a; Minneapolis, MN), or eBioscience
(CD8, Lag3, CD160, 2B4, CD45.1, CD45.2, CD107a, Eomes). MHC class I peptide
tetramers were made and used as described previously (Wherry et al., 2003a; Kao et al.,
2011). Poly-caspase analysis was performed with Flica Vybrant FAM Poly Caspases
Assay Kit (Life Technologies). Data were collected on a BD LSRII (BD Biosciences) and
analyzed with FlowJo software (Tree Star). Cell sorting was performed using a BD Aria II
(BD Biosciences).

3.2.4: BrdU Treatment and Detection
Animals were treated with 2mg of BrdU (Sigma-Aldrich) i.p. daily for 1-5 days
prior to tissue harvest and analysis. BrdU incorporation was assessed by the BrdU Flow
Kit per manufacturer’s instructions (BD Biosciences).
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3.2.5: In vitro Stimulation
Naïve WT and PD-1 KO P14 cells were isolated from spleens by CD8 negative
selection (Stem Cell Technologies) and cultured in RPMI-1640 medium in the presence
of recombinant human IL-2 (100 U/mL; R&D Systems.) Naive P14 cells were stimulated
for 4d by co-culturing with GP33 peptide-pulsed naïve splenocytes.

3.2.6: Statistical Analysis
Student’s t-test (Paired and Unpaired) were performed using Prism software
(Graphpad).

3.3: Results
3.3.1: Co-adoptive transfer strategy allows for examination of PD-1
deficient virus-specific CD8+ T cells during chronic LCMV infection
Direct infection of PD-1 or PD-L1 KO mice with LCMV clone 13 causes lethal
immunopathology. Previous studies using adoptive transfer of LCMV-specific TCRtransgenic CD8+ T cells (P14 cells) also resulted in immunopathology when 104 PD-1
KO P14 cells were transferred (Frebel et al., 2012; Barber et al., 2006). We
hypothesized that using lower numbers of P14 cells would avoid immune-mediated
damage, allowing for analysis of PD-1 KO P14 cell exhaustion during chronic infection.
Thus, a co-adoptive transfer strategy was employed in which equal numbers of WT and
PD-1 KO P14 cells were transferred into congenically-disparate WT mice, followed by
infection with LCMV clone 13 (Figure 3.1A and 3.1B). This strategy allows for direct
comparison of WT and PD-1 KO P14 cell responses in the same recipient mice during
chronic viral infection while controlling for precursor frequency, TCR repertoire, viral
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load, inflammatory environment, and immunopathology. To determine if this co-adoptive
transfer strategy mitigated alterations in viral load and/or morbidity that occur as a result
of P14 transfer, viremia and adjusted survival were assessed in mice that received
varying numbers of WT and PD-1 KO P14 cells (Pircher et al., 1989; Blattman et al.,
2009; Frebel et al., 2012). Transfer of greater than 1000 total P14 cells (500 WT + 500
PD-1 KO) resulted in reduced viral load (Figure 3.1C) and significant morbidity (Figure
3.1D) in mice compared to no P14 transfer, consistent with previous reports (Frebel et
al., 2012). However, transfer of 500 total P14 cells (250 WT + 250 PD-1 KO) did not
alter significantly viremia or morbidity during chronic LCMV infection compared to mice
that did not receive P14 cells (Figure 3.1C and 3.1D). These results demonstrate that a
co-adoptive transfer approach with small numbers of WT and PD-1 KO P14 cells can be
used to address the development of CD8+ T cell exhaustion in the absence of cellintrinsic PD-1 signals.
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Figure 3.1: Adoptive transfer of WT and PD-1 KO P14 cells as a model to study T
cell exhaustion in the absence of PD-1. (A) Schematic of co-adoptive transfer model.
(B) Representative FACS plots of gating scheme for WT and PD-1 KO P14 cells. P14
cells are gated from total CD8+ T cells (far left) by expression of H-2Db GP33 tetramer,
congenic markers, and PD-1. (C) Longitudinal analysis of viral load in serum of mice that
received indicated numbers of WT and PD-1 KO P14 cells followed by infection with
LCMV clone 13 (+/- s.e.m.), *p < 0.05 (unpaired Student’s t-test). (D) Survival curve of
mice that received indicated numbers of WT and PD-1 KO P14 cells following LCMV
clone 13 infection. “Adjusted Survival” indicates time to loss of >25% of total body weight
and subsequent euthanasia.
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3.3.2: CD8+ T cell exhaustion develops in the absence of PD-1
Previous studies demonstrating potent inhibition of CD8+ T cells by the PD-1
pathway suggest that PD-1 may be essential for the development of T cell exhaustion
(Barber et al., 2006; Parry and Riley, 2005; Okazaki et al., 2013). Thus, we tested the
hypothesis that PD-1 KO P14 cells would not become exhausted during chronic LCMV
infection. First, we examined the ability of WT versus PD-1 KO P14 cells to produce
cytokines at d42 p.i. following ex vivo peptide re-stimulation. At this time-point, WT P14
cells showed signs of classical exhaustion. Compared to control memory P14 cells
generated following acute LCMV infection, these exhausted P14 cells less efficiently
produced IFN-γ (average of 86% vs 51%) or co-produced IFN-γ and TNF-α (average of
76% vs 8%) (Figure 3.2A). Surprisingly, production of IFN-γ and TNF-α was even more
severely reduced in the PD-1 KO P14 population, with an average of only 39% of cells
producing IFN-γ and 1.6% of cells co-producing IFN-γ and TNF-α (Figure 3.2A). In
addition, PD-1 KO P14 cells developed a significant reduction in IFN-γ production per
cell, as evidenced by lower MFI of IFN-γ expression compared to WT P14 cells in the
same mice (data not shown). PD-1 KO P14 cells also exhibited reduced polyfunctionality compared to WT P14 cells, with minimal co-production of IFN-γ, TNF-α, and
Mip1-α (Figure 3.2B). However, the ability to de-granulate, as measured by LAMP1/CD107a expression, was retained (Figure 3.2B). Analysis of WT and PD-1 KO P14
cells in separate mice resulted in similar findings, confirming the CD8+ T cell intrinsic
nature of this effect (Figure 3.2C).
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Figure 3.2: Severe loss of exhausted CD8+ T cell cytokine production in the
absence of PD-1. (A) Intracellular cytokine staining for IFN-γ and TNF-α after
stimulation with GP33 peptide (left). Values indicate frequency of P14 cells producing
IFN-γ and/or TNF-α for individual (left) and multiple mice (right) at d42 p.i. in the spleen
(B) Intracellular staining for Mip1-α and CD107a after stimulation with GP33 peptide
(left). Values indicate frequency of P14 cells producing Mip1-α and/or CD107a for
individual (left) and multiple mice (right) at d42 p.i. in the spleen.

(C) Intracellular

cytokine staining for IFN-γ and TNF-α after stimulation with GP33 peptide from mice with
separate transfer of WT or PD-1 KO P14 cells compared to mice with co-transferred WT
and PD-1 KO P14 cells (left). Values indicate frequency of P14 cells co-producing IFN-γ
and TNF-α for individual (left) and multiple mice (right). (+/- s.e.m.) *p < 0.05 **p < 0.01
(paired Student’s t-test)
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Reduced cytokine production in the absence of PD-1 also corresponded with
higher expression of multiple other inhibitory receptors, a second key feature of
exhaustion. PD-1 KO P14 cells expressed higher Lag-3, 2B4, CD160, and Tigit than WT
P14 cells at day 42 p.i. (Figure 3.3A and 3.3B). A higher frequency of PD-1 KO P14
cells also simultaneously co-expressed Lag-3, 2B4, Tim-3 and CD160 compared to WT
(Figure 3.3C). These findings indicate that CD8+ T cell exhaustion can develop in the
absence of PD-1. In fact, two defining features of exhausted CD8+ T cells, loss of
cytokine poly-functionality and elevated inhibitory receptor co-expression, were more
severe when CD8+ T cell intrinsic PD-1 signals were absent.
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Figure 3.3: Increased inhibitory receptor expression on exhausted CD8+ T cells in
the absence of PD-1. (A) Expression of indicated inhibitory receptors on naïve CD8+ T
cells, WT P14 cells, and PD-1 KO P14 cells at d42 p.i. in the spleens of representative
mice. Values indicate MFI of expression. (B) Summary of inhibitory receptor MFI on WT
and PD-1 KO P4 cells at d42 p.i. in the spleen (C) Boolean gating analysis of the
simultaneous expression of multiple inhibitory receptors (Lag-3, 2B4, CD160 and Tim-3)
on WT and PD-1 KO P14 cells at d42 p.i. in the spleen. Pie charts display individual
populations grouped according to total number of inhibitory receptors expressed (left).
Bar graph displays relative abundance of each possible individual inhibitory receptor
expression profile (right). (+/- s.e.m.) *p < 0.05 **p < 0.01 ***p < 0.001 (paired Student’s
t-test).
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3.3.3: Despite early signs of dysfunction, PD-1 deficient CD8+ T cells
proliferate robustly during the acute phase of infection
We next investigated if this increased exhaustion in the absence of PD-1 started
early during chronic infection. To test this, the phenotype and function of WT and PD-1
KO P14 cells was analyzed at the peak of the effector response, d8 post-infection. Both
WT and PD-1 KO P14 cells were highly capable of producing IFN-γ at d8 p.i. (Figure
3.4A), consistent with previous work (Parry and Riley, 2005; Frebel et al., 2012;
Patsoukis et al., 2012; Yokosuka et al., 2012). However, PD-1 KO P14 cells displayed a
subtle, but significant, reduction in production of IFN-γ and co-production of IFN-γ and
TNF-α (Figure 3.4A). PD-1 KO P14 cells also had elevated expression and coexpression of several other inhibitory receptors at this time-point (Figure 3.4B and data
not shown). Taken together, these data suggest that dysfunction of PD-1 KO P14 cells
may begin early during the course of chronic infection. However, despite slight defects in
cytokine production and elevated inhibitory receptor expression, PD-1 KO P14 cells
greatly outnumbered WT P14 cells in the spleen, blood, and other organs at d8 p.i.
(Figure 3.5A and data not shown). Therefore, we hypothesized that loss of PD-1
signals might improve the activation and proliferation of virus-specific CD8+ T cells. In
the first few days following T cell activation, PD-1 KO P14 cells had a trend towards a
proliferative advantage from d2-3 p.i. in the spleen compared to WT P14 cells, but there
was no difference in proliferation by d4 p.i. (Figure 3.5B). There was also no difference
in the early proliferation of WT versus PD-1 KO P14 cells when co-cultured with GP33
peptide-pulsed splenocytes in vitro (Figure 3.5B). However, PD-1 KO P14 cells
proliferated significantly more robustly than WT P14 cells between d7-8 p.i., as
measured by Ki67 expression (Figure 3.5C) and BrdU incorporation (Figure 3.5D).
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Despite this robust prolieration, WT and PD-1 KO P14 cells had similar expression of
activation and differentiation markers, such as CD69, KLRG-1, CD27, CD44, CD62L,
and CD25 during early activation (d1-4 p.i.) and during the effector phase (d8 p.i.) (data
not shown). These findings suggest that PD-1 restricts virus-specific CD8+ T cell
responses during chronic infection primarily by restraining proliferation during the
effector phase. These data also suggest that control of proliferation during the effector
phase corresponds with the degree of preservation of T cell function in the chronic
phase of infection.

68

%A

JK-''LM(NF(KO<O
105

FI0

#$%&'()()*+(,'--

FOF0

$#"a

104

105

F*0

$#"a.(/0(12()*+(,'--34

!"()*+(,'--

:OG0

104

10

3

10

10

2

102

0

0

0

10

2

10

3

10

4

10

3

5

0

10

2

10

3

10

4

10

100

80
70
60

!"#_

&B

95*:;

WT PD-1 KO

?@+

N

15

**
10

5

!
C

0

1500

***

WT PD-1 KO

!<B<C

1000

!<=6>

***

"%<D'(
E!
)56*(78

+IH
:?I
0

102

103

104

105

+IH
G:?
0

102

103

104

105

>;+
++;
0

102

103

104

105

+FG
:?G
0

102

'

103

104

105

HG;
*;I;
0

102

103

104

105

***

***

500

,

)*
"#$%&'(

+,-

A%B6>

*

90

50

5

$#"a.!"#_.(/0(12()*+(,'--34

Figure 3.4

0

**

CD160 2B4

Lag-3

Tigit

Tim-3

2

Figure 3.4: Early signs of CD8+ T cell exhaustion in PD-1 KO P14 cells. (A)
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(left) and multiple mice (right) at d8 p.i. in the spleen. (B) Expression of indicated
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p.i. in the spleens of representative mice and multiple mice (C) Values indicate MFI of
expression. Data are representative of 3 independent experiments with 5-8 mice per
group. (+/- s.e.m.) *p < 0.05 **p < 0.01 ***p < 0.001 (paired Student’s t-test).
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Figure 3.5
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Figure 3.5: Increased expansion and proliferation of PD-1 KO P14 cells during
effector phase (A) Absolute number of WT and PD-1 KO P14 cells at d8 p.i. in the
spleen (+/- s.e.m.). (B) Expression of CellTraceViolet on WT and PD-1 KO P14 cells on
indicated days post-infection with LCMV clone 13 in the spleen (left) or following in vitro
stimulation with GP33-pulsed splenocytes (right). (C) Expression of Ki67 on WT and PD1 KO P14 cells at d8 p.i. in the spleen (D) Expression of CD44 versus BrdU
incorporation in WT and PD-1 KO P14 cells at d8 p.i. in the spleen following 24h BrdU
pulse. Values indicate frequency of P14 cells positive for BrdU based on FMO staining
control. (+/- s.e.m.), *p < 0.05 **p < 0.01 *** p < 0.001 (paired Student’s t-test). All data
are representative of 2-5 independent experiments with 5-8 mice per group.
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3.3.4: Decreased survival of CD8+ T cells after the effector phase in the
absence of PD-1
Because of the increased proliferation of PD-1 KO P14 during the effector phase,
we next examined how the absence of PD-1 affected the transition to later stages of
infection. After initial expansion, PD-1 KO P14 cells underwent a significantly greater
contraction between days 15-42 p.i. (88% decrease) compared to WT P14 cells (75%
decrease) (Figure 3.6A). We hypothesized that this more dramatic contraction was due
to decreased survival in the absence of inhibitory signals from the PD-1 pathway. To test
this, WT and PD-1 KO P14 cells were assessed for markers of cell death between days
14-20 p.i. in the spleen. A higher frequency of PD-1 KO P14 cells expressed Live/dead
Aqua (Figure 3.6B) and Annexin V (Figure 3.6C), markers of compromised cell
membrane integrity that are associated with apoptosis and cell death. PD-1 KO P14
cells also displayed increased staining with fluorescent caspase substrates (FLICA) at
d15 p.i. (Figure 3.6D). In addition, ex vivo survival of PD-1 KO P14 cells was decreased,
as demonstrated by a significant reduction in the total frequency of live cells remaining
after a 10-hour in vitro culture (data not shown). Thus, in the absence of PD-1, virusspecific CD8+ T cells experience considerably more cell death than WT CD8+ T cells of
the same specificity in the same inflammatory environment. These findings suggest that
PD-1 prevents over-stimulation of CD8+ T cells and subsequent excessive cell death
during chronic viral infection.
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Figure 3.6: Reduced survival of PD-1 KO P14 cells during T cell contraction. (A)
Fold decrease in frequency of WT and PD-1 KO P14 cells from peak of T cell response
(d15 p.i.) to chronic phase of infection (d42 p.i.). Values indicate average fold decrease
for each population (+/- s.e.m.), *p < 0.05 (unpaired Student’s t-test). (B) Expression of
Live/dead Aqua and (C) Annexin V in WT and PD-1 KO P14 cells at d18 p.i. in the
spleen for individual (histograms) and multiple mice (bar graphs) (+/- s.e.m.). Values
indicate frequency of P14 cells positive for staining based on FMO staining controls. (D)
Expression of CD44 versus FLICA in WT and PD-1 KO P14 cells at d14 p.i. in the
spleen for individual (left) and multiple mice (right). Values indicate frequency of P14
cells positive for FLICA dye based on FMO staining control, *p < 0.05 **p < 0.01 (paired
Student’s t-test). All data are representative of 2-4 independent experiments with at least
5 mice per group.
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3.3.5: Decreased proliferation and long-term durability of PD-1 KO
exhausted CD8+ T cells
The increase in cell death of PD-1 KO P14 cells suggests that long-term
durability of virus-specific CD8+ T cells may be compromised in the absence of PD-1.
During LCMV clone 13 infection, the frequency and absolute number of WT P14 cells
began to stabilize in the spleen and blood between d22-42 p.i. (Figure 3.7A and data
not shown). PD-1 KO P14 cells, in contrast, declined in both frequency and absolute
number until d42 p.i., suggesting that long-term durability of virus-specific CD8+ T cell
responses may be compromised in the absence of PD-1 (Figure 3.7A). However,
viremia during LCMV clone 13 infection of B6 mice gradually resolves by d40-60 p.i,
complicating the interpretation of changes in exhaustion at late time-points. Therefore,
we utilized a model of exhaustion where transient depletion of CD4+ T cells prior to
infection with LCMV clone 13 leads to persistent, life-long high viremia (Matloubian et al.,
1994). As observed in CD4+ T cell-sufficient clone 13 infection, WT P14 cell responses
stabilized in frequency and absolute number after d48 p.i. in CD4+ T cell-depleted mice
(Figure 3.7B). In contrast, while PD-1 KO P14 cell numbers were higher than WT P14
cells, the number of PD-1 KO P14 cells failed to stabilize and continued to decline for
many months (Figure 3.7B). The inability of PD-1 KO P14 cells to form a stable, longterm population of exhausted CD8+ T cells in the spleen could be due, at least in part, to
the increased cell death observed in this population. However, on-going antigen-driven
proliferation is central to the durability of exhausted CD8+ T cell populations (Paley et
al., 2012; Shin et al., 2007). Given the early robust expansion of virus-specific CD8+ T
cells in the absence of PD-1, we asked if PD-1 KO P14 cells were able to sustain this
proliferation into the chronic phase of infection. PD-1 KO P14 cells had dramatically
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reduced expression of Ki67 at d42 p.i. in both CD4+ T cell-sufficient (clone 13) and
CD4+ T cell-depleted (clone 13 + GK1.5) mice (Figure 3.7C). In addition, PD-1 KO P14
cells incorporated significantly less BrdU from days 35-42 p.i. than WT P14 cells (data
not shown). Taken together, these findings suggest that increased cell death and loss of
sustained proliferative ability contribute to the deceased stability of PD-1 KO P14 cells in
chronic infection.
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Figure 3.7: Diminished long-term proliferation and stability of CD8+ T cells in the
absence of PD-1. (A) Longitudinal analysis of frequency (left) and absolute numbers
(right) of WT and PD-1 KO P14 cells in the spleen during LCMV clone 13 infection. (B)
Longitudinal analysis of absolute number of WT and PD-1 KO P14 cells in the spleen of
mice treated with anti-CD4-antibody at d-1 and d1 of LCMV clone 13 infection. (C)
Expression of PD-1 versus Ki67 in WT and PD-1 KO P14 cells at d42 p.i. in the spleen
during infection with LCMV clone 13 with or without CD4 depletion. Values indicate
frequency of P14 cells positive for Ki67 (+/- s.e.m.), *p < 0.05 **p < 0.01 (paired
Student’s t-test). All data are representative of 3 independent experiments with at least 5
mice per group.
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3.3.6: PD-1 controls exhausted CD8+ T cell proliferative dynamics by
regulating Tbethi and Eomeshi subsets
Recent work has demonstrated that two subsets of exhausted CD8+ T cells,
Tbethi progenitors and Eomeshi progeny, exist in a proliferative hierarchy to sustain longterm CD8+ T cell responses during chronic viral infections (Paley et al., 2012). Based on
these observations, we next investigated whether loss of PD-1 impacted the balance
between these two subsets and if changes in these subsets could account for the altered
proliferation and stability of the PD-1 KO P14 population. To test this idea, we assessed
expression of Tbet and Eomes at days 8, 15 and 42 p.i. in WT and PD-1 KO P14 cells.
At day 8 p.i., increased expression of both Tbet and Eomes was observed in PD-1 KO
P14 cells, which is consistent with the increased activation of these cells early in
infection (Figure 3.8A). However by day 15 p.i., PD-1 KO P14 cells had a significant
decrease in Tbet MFI (Figure 3.8A) that was followed by a dramatic loss of Tbethi cells
at day 42 p.i. (Figure 3.8B and Figure 3.8C). This loss of Tbethi cells corresponded with
a skewing of the PD-1 KO P14 cell population towards the Eomeshi subset, as
demonstrated by an increase in both frequency of Eomeshi cells and Eomes MFI at d15
(Figure 3.8A) and 42 p.i. (Figure 3.8B and Figure 3.8C). We next asked if this change
in Tbet observed in exhausted PD-1 KO P14 cells truly represented a shift in subset
dynamics to Eomeshi progeny. To test this idea, PD-1 KO P14 cells were assessed for
other cardinal features of Eomeshi cells (Paley et al., 2012). PD-1 KO P14 cells, like WT
Eomeshi exhausted CD8+ T cells, were significantly increased in frequency in peripheral
tissues, including the bone marrow and liver (Figure 3.9A).
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Figure 3.8: Altered dynamics of exhausted CD8+ T cell subsets in the absence of
PD-1. (A) Expression of Tbet and Eomes in WT and PD-1 KO P14 cells in the spleen at
d0 (naïve), d8 and d15 p.i. with LCMV clone 13 (+/- s.e.m.) (B) Expression of Tbet
versus Eomes in WT and PD-1 KO P14 cells at d42 p.i. in the spleen of individual (top)
and multiple mice (bottom). Values indicate frequency of P14 cells that are T-bethi
Eomeslo or Eomeshi T-betlo (C) Representative plots of MFI of Tbet and Eomes
expression in WT (black) and PD-1 KO (red) P14 cells at d42 p.i. in the spleen **p < 0.01
(paired Student’s t-test). All data are representative of 2-5 independent experiments with
at least 5 mice per group.
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Key functional properties of Eomeshi cells were also observed in PD-1 KO P14
cells. Despite decreased cytokine production (Figure 3.2A) and proliferation (Figure
3.7C), PD-1 KO P14 cells possessed higher cytotoxicity than WT P14 cells (Figure
3.9B), as well as increased expression of Granzyme B at d42 p.i. (Figure 3.9C). This is
also consistent with the high expression of multiple inhibitory receptors observed on both
PD-1 KO P14 cells and WT Eomeshi cells (Figure 3.3A and Figure 3.3B). Thus, PD-1
KO P14 cells accumulate mainly as terminally-differentiated Eomeshi progeny. These
findings suggest that PD-1 controls proliferation dynamics during chronic viral infection,
at least in part, by preventing loss of Tbethi progenitor cells. In addition to changes in
proliferation, loss of PD-1 signals leads to an exhausted CD8+ T cell pool with more
extensive tissue distribution and enhanced cytotoxicity, which may be an important
consideration when using PD-1 blockade for chronic infections and cancer.
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Figure 3.9
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Figure 3.10
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Figure 3.10: Model of the role for PD-1 in the development of CD8+ T cell
exhaustion during chronic viral infection. In WT settings (black), PD-1 tempers the
early activation and proliferation of CD8+ T cell responses to chronic infection, promoting
survival of exhausted CD8+ T cells into the chronic phase of infection and the
establishment of Tbethi and Eomeshi subsets. In contrast, PD-1 deficiency (red) leads to
the hyper-activation and excessive proliferation of early CD8+ T cell responses to
chronic infection, resulting in increased cell death. This is associated with loss of the
Tbethi subset of exhausted CD8+ T cells and the accumulation of terminallydifferentiated Eomeshi cells. As a result, PD-1 deficient exhausted CD8+ T cells exhibit
unique functional properties and have largely lost their antigen-dependent proliferative
ability, resulting in decreased population stability long-term.
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3.3.7: Discussion
Expression of the inhibitory receptor PD-1 is strongly associated with CD8+ T cell
exhaustion in chronic infection and cancer. The ability to partially restore T cell functions
by PD-1/PD-L1 pathway blockade suggests a fundamental link between this pathway
and the development of CD8+ T cell exhaustion (Barber et al., 2006; Freeman et al.,
2006; Petrovas et al., 2006; Blank et al., 2005; Wherry, 2011). A key unanswered
question, however, is whether or not PD-1 directly causes or induces T cell exhaustion.
Here, we tested this idea using approaches that control for a number of confounding
issues that previously obscured clear answers to this question. We found that genetic
absence of PD-1 on antigen-specific CD8+ T cells did not prevent exhaustion during
chronic LCMV infection. Consistent with the negative regulatory role of this pathway,
CD8+ T cell expansion was greatly enhanced by the absence of PD-1 during the acute
phase of infection (Barber et al., 2006; Parry and Riley, 2005; Patsoukis et al., 2012;
Okazaki et al., 2013). However, PD-1 deficiency also led to increased apoptosis during
the contraction phase. Moreover, permanent absence of PD-1 resulted in the
dysregulation of a key proliferative hierarchy required to sustain exhausted CD8+ T cell
populations during chronic infection. Without PD-1, exhausted CD8+ T cells
accumulated as Eomeshi cells, while the T-bethi progenitor pool was depleted. In addition,
this shift was accompanied by functional changes associated with an altered balance of
these subsets. Cytokine production declined in the absence of PD-1 due to loss of the
slightly more functional T-bethi population, but cytotoxicity was improved since the
Eomeshi subset has better killing capacity. These findings reveal an unexpected dual
role for PD-1 signals during chronic viral infection.

While PD-1 clearly negatively

regulates CD8+ T cell responses during the chronic phase of infection (Barber et al.,
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2006; Wherry, 2011), this pathway also plays a critical role in protecting exhausted
CD8+ T cells from excessive stimulation, terminal exhaustion and erosion of the
population over time. These findings have implications for prolonged clinical treatments
with PD-1 pathway antagonists where the benefit of rejuvenating exhausted CD8 T cells
may have to be balanced with the risk of over-stimulation and lack of long-term stability.
While complete genetic absence of PD-1 is unlikely to manifest clinically, several
important genetic variants in and around the PDCD1 gene have been described that are
associated with autoimmunity, cancer prognosis or chronic viral infection (James et al.,
2005; Zhang et al., 2012; Velázquez-Cruz et al., 2007; Muenst et al., 2010). While
mechanistically it remains unclear how most of these genetic variants affect the
expression or function of PD-1, these observations do suggest that genetic variation in
the PD-1 pathway could be an important parameter affecting the development of T cell
responses in humans.

It will be interesting to determine whether there are any

relationships between these human PDCD1 polymorphisms and changes in the
development and/or dynamics of exhausted T cells we have observed in mice. The
potential impact of genetic variation in genes in the PD-1 pathway and outcomes of
clinical PD-1 treatments remains to be defined. In addition to natural genetic variation, it
is now possible to genetically engineer T cells for adoptive immunotherapeutic
approaches (Restifo et al., 2012). PD-1 might be an interesting target to consider in
such therapeutically modified T cell adoptive immunotherapy approaches. However, our
data suggest that such approaches to modify or genetically ablate PD-1 should be
considered with caution.
One interesting aspect of the PD-1 deficient CD8+ T cell response that develops
during chronic LCMV infection is the elevated expression of many other inhibitory
receptors.

In the absence of PD-1, we observed higher expression of Lag-3,
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2B4/CD244, CD160, and Tigit.

Most, if not all, of these inhibitory receptors are

upregulated following TCR signaling in acutely activated T cells and their elevated
expression by PD-1 deficient CD8+ T cells may indicate a greater degree of ongoing
TCR stimulation. These observations are consistent with the idea that TCR signaling is
increased in the absence of PD-1 and that PD-1 is an essential rheostat or tuner of in
vivo TCR signaling (Okazaki et al., 2013; Honda et al., 2014).

In addition, the

upregulation of other inhibitory receptors in the absence of PD-1 signals could partially
explain the synergy observed during co-blockade of PD-1 and other inhibitory receptors
and reveal opportunities for targeting other inhibitory receptors in conjunction with PD-1.
Thus, these observations support use of co-blockade of multiple inhibitory receptors in
cancer patients for optimal reversal of T cell exhaustion. This issue will be interesting to
examine clinically as the timing and/or sequence with which different inhibitory receptor
blockades are introduced may influence the therapeutic outcome.
Our data provide a cellular mechanism to explain the population-based effects of
PD-1 deficiency during chronic infection. PD-1 appears critical for regulation of a
proliferative hierarchy necessary to maintain exhausted CD8+ T cell populations. We
have previously described a lineage relationship within the exhausted CD8+ T cell pool
where exhausted PD-1int T-bethi cells give rise to PD-1hi Eomeshi cells. This transition is
driven by persisting antigen and is accompanied by extensive division, downregulation of
T-bet and upregulation of Eomes (Paley et al., 2012). These Eomeshi progeny are
terminally differentiated and lack future proliferative capacity (Paley et al., 2012). Such
exhausted CD8+ T cells subsets are found not only in chronic LCMV infection of mice,
but also in human HCV and HIV infection.

Our current data indicate a critical, but

perhaps somewhat paradoxical, role for PD-1 in this proliferative hierarchy. Without PD1, exhausted CD8+ T cells accumulate as Eomeshi terminally differentiated progeny.
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This observation suggests that permanent loss of PD-1 signals may progressively erode
exhausted CD8+ T cell populations. These data also indicate that PD-1 tempers the
continual activation and differentiation of the T-bethi progenitor pool, in effect protecting
this subset from chronic overstimulation and preserving these cells for future activation
and generation of terminal progeny. Previous work demonstrated that T-bet directly
represses expression of the PDCD1 gene (Kao et al., 2011). In addition, persisting
antigen stimulation can lead to loss of T-bet expression (Kao et al., 2011; Paley et al.,
2012). Taken together, these observations suggest a model whereby PD-1 inhibits TCR
signaling during chronic infection, which helps maintain T-bet expression. T-bet, in turn,
prevents the highest level of PD-1 expression that may preserve cytokine production and
proliferative potential in the Tbethi progenitor population.

We would predict that

variations in antigen and/or viral load would lead to an imbalance in this feedback loop.
Settings of high antigen stimulation may favor the activation and proliferation of Tbethi
progenitors followed by loss of T-bet expression, further upregulation of PD-1 and
Eomes expression and, ultimately, terminal differentiation. Thus, our data suggest a
novel dual role for PD-1 signals in negatively regulating CD8+ T cell proliferation and
function during chronic infection, but also in sustaining Tbethi progenitor cells, a
population critical for a proliferative hierarchy that contains chronic infection.
In summary, we have identified a novel role for the PD-1 pathway in regulating
CD8+ T cell exhaustion during chronic viral infection. PD-1 signals are critical for
preventing the early over-activation and proliferation of CD8+ T cells in response to
chronic infection, thus promoting the establishment and stability of exhausted T cell
responses. Additional work will be necessary to further characterize the molecular
pathways regulated by PD-1 in exhausted CD8+ T cells and to compare genetic loss of
PD-1 to the more clinically relevant setting of PD-1 pathway blockade.
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Chapter 4: Concluding Remarks and Future Directions

4.1 Overview of Results
The PD-1 pathway regulates T cell activation and function by inhibiting TCR and
co-stimulatory signals. A previously unresolved question, however, is how PD-1 pathway
inhibition impacts the differentiation of CD8+ T cells in settings of acutely-resolved or
chronic infection. In chapter 2 of this thesis, the role of PD-1 signals in the development
of effector and memory CD8+ T cells during acutely-resolved influenza infection was
investigated. While loss of PD-1 or PD-1 ligands enhanced the expansion of effector
CD8+ T cells, the development of long-lasting CD8+ T cell memory responses was
impaired. Defects in the magnitude of the response, as well as in cytokine production
and recall capacity of memory CD8+ T cells were observed in the absence of the PD-1
pathway. Thus, the inhibition of effector CD8+ T cell responses by PD-1 signals
promotes the generation and longevity of memory responses in a setting of acutelyresolved infection (Figure 2.11).
The PD-1 pathway also plays a prominent role in settings of chronic antigen
stimulation and CD8+ T cell exhaustion, including chronic infections and cancer.
Previous work has demonstrated regulation of established exhausted CD8+ T cell
responses by the PD-1 pathway; however, the role of PD-1 signals in the development
of CD8+ T cell exhaustion is not well understood. In chapter 3 of this thesis, PD-1
signals were shown to inhibit the early proliferation and expansion of virus-specific CD8+
T cells during chronic LCMV infection. Loss of PD-1 from the onset of infection, however,
resulted in increased cell death during the contraction phase. Ultimately, PD-1 deficiency
led to more severe dysfunction of cytokine production and proliferation in the chronic
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phase of infection. However, PD-1 deficient CD8+ T cells retained cytotoxic ability and
had enhanced infiltration into peripheral tissues. This PD-1-deficient exhaustion
phenotype was associated with loss of Tbethi progenitor cells and the accumulation of
terminally-differentiated Eomeshi progeny (Figure 3.10).
Taken together, chapters 2 and 3 of this thesis demonstrate a critical role of PD-1
signals in restricting the early activation, proliferation and expansion of CD8+ T cells
during both acutely-resolved and chronic infections. Importantly, this early regulation of
CD8+ T cell responses by the PD-1 pathway has profound long-term consequences on
the development of memory or exhausted T cell responses. PD-1, therefore, acts to tune
CD8+ T cell responses, allowing for a robust and effective anti-pathogen response but
balancing this with the need generate long-lived memory or exhausted responses. This
work has important implications for clinical targeting of the PD-1 pathway in both
prophylactic vaccination and therapeutic treatment strategies. Given the recent FDA
approval of PD-1 blocking monoclonal antibodies (FDA.gov), these novel roles for PD-1
should also be considered when designing therapy regimens.

4.2 Context dependent roles of PD-1 on CD8+ T cells
PD-1 has been demonstrated to modulate T cell responses in many areas of
disease, including auto-immunity, cancer and infections (Francisco et al., 2010; Okazaki
et al., 2013). In all of these settings, PD-1 plays a role in “tuning” the threshold of TCR
activation; however, it has become apparent in recent years that PD-1 has unique,
context-dependent functions, as well. Chapters 2 and 3 of this thesis expand on this
idea and identify novel similarities and differences in how PD-1 regulates the CD8+ T
cell response to acutely-resolved vs. chronic viral infection. Specifically, the factors that
seem to impact PD-1 mediated inhibition of CD8+ T cells include: the strength of TCR
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stimulation, the duration of antigen exposure and the anatomical location of TCR:antigen
signals. Below, these factors will be discussed in the context of the findings in this thesis.

4.2.1 PD-1 and TCR signal strength
The idea that strength of TCR:antigen stimulation impacts the extent of PD-1
mediated inhibition has been investigated in several in vitro settings (Bennett and
Carreno, 2002; Yokosuka et al., 2012; Parry and Riley, 2005; Freeman et al., 2000b).
Using a titration of CD3 and CD28 concentrations, Freeman et al. demonstrated that PD1 inhibition of T cell proliferation was most robust at low or suboptimal levels of TCR
engagement and CD28 signaling. However, higher or more optimal levels of TCR and
CD28 signals seemed to circumvent the negative effects of PD-1 ligation (Freeman et
al., 2000a). These studies were the first to suggest that the consequences of PD-1/L1
ligation depend on the strength of signaling through TCR and CD28. Recently, additional
in vitro work has demonstrated that the level of PD-1 expression on the cell surface also
impacts the amount of T cell inhibition, with higher levels of PD-1 corresponding with
greater inhibition of T cell activation and functions (Wei et al., 2013). Importantly, it is the
amount of PD-1 within the immunological synapse that appears to be most relevant
(Yokosuka et al., 2012). These ideas are consistent with work presented in chapter 2 of
this thesis, where differences in PD-1 mediated inhibition in vivo seemed to correspond
with TCR signal strength. For example, CD8+ T cells specific for sub-dominant epitopes
of influenza seem to be most dramatically impacted by loss of PD-1 pathway signals. It
may be that, within the same environment, CD8+ T cells with a TCR that receives lower
levels of stimulation are more sensitive to PD-1-mediated inhibition, consistent with
previous in vitro findings. Similar observations have been made anecdotally in our lab
during LCMV clone 13 infection. Previous work has demonstrated that different epitopes
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of LCMV receive different “levels” of epitope presentation (Wherry et al., 2003a). These
varying amounts of TCR stimulation correlate with different outcomes of CD8+ T cell
exhaustion. For example the NP396 epitope is displayed at high levels during LCMV
clone 13, which results in rapid exhaustion and clonal deletion of NP396-specific CD8+ T
cells. Other epitopes of LCMV, such as GP33 and G276, have lower MHC class 1
binding affinities and T cell stimulatory capacities. As a result, GP33-specific and
GP276-specific CD8+ T cells become functionally exhausted but not clonally deleted
(Wherry et al., 2003a). Unpublished work in our lab suggests that virus-specific CD8+ T
cells that receive less TCR stimulation in vivo during chronic viral infection, particularly
GP276-specific CD8+ T cells, are most responsive to PD-1 pathway blockade. This
would be consistent with the idea that the TCR signal strength is a major contributing
factor to the extent of PD-1 pathway inhibition in vivo during both acutely-resolved and
chronic infections.

4.2.2: PD-1 and duration of antigen stimulation
The duration of antigen stimulation is another critical parameter that impacts PD-1
pathway inhibition. An example of this is demonstrated in chapters 2 and 3 of this
thesis, where absence of cell-intrinsic PD-1 results in different outcomes for CD8+ T cell
responses to acutely-resolved influenza infection and chronic LCMV infection. Although
there are many differences between influenza infection vs. LCMV clone-13 infection, PD1 deficient P14 cells were used in both settings allowing for comparison of CD8+ T cells
with same TCR specificity and affinity in the context of different durations of antigen
exposure. Absence of PD-1 led to robust proliferation and expansion during the effector
phase of acute influenza infection and chronic LCMV infection, a period when pathogen
load is high in both settings. It should also be noted that this is a period when PD-1
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expression is also normally elevated during acute or chronic infections. However, the
role of PD-1 on the long-term CD8+ T cell responses is different following either the
clearance or persistence of pathogen. PD-1 KO P14 cells upregulate properties of
memory CD8+ T cells following acutely-resolved influenza infection, including cytokine
production, recall capacity, and phenotypic memory markers. In contrast, during chronic
LCMV infection, PD-1 KO P14 cells become severely exhausted, up-regulate multiple
other inhibitory receptors and become terminally-differentiated. It may be that the
continued exposure of virus-specific CD8+ T cells to antigen during chronic infection
requires the counter-balance of inhibitory signals from PD-1. Thus, absence of PD-1 in
settings of persistent antigen may be more detrimental to the long-term phenotype,
function and survival of CD8+ T cells. Of note, despite these very different functional
outcomes, in both settings of acutely-resolved and chronic infection loss of PD-1
pathway signals results in more defective memory or exhausted CD8+ T cell responses
compared to wildtype CD8+ T cells.

4.2.3: PD-1 and anatomical location
The anatomical location of TCR:antigen and PD-1:PD-L1/2 interactions also seems
to be an important factor in the amount of PD-1 mediated inhibition. Several studies
support the idea that the “tuning” function of PD-1 protects the host from immunemediated damage, particularly in sensitive and inflamed tissues (Frebel et al., 2012;
Honda et al., 2014; Okazaki et al., 2013). For example, recent work has described that
PD-1/PD-L1 signals are part of a regulatory mechanism that prevents prolonged T cell
responses in inflamed tissues. Honda et al. show that PD-1 inhibits antigen-driven CD4+
T cell arrest and subsequent effector functions in a model of delayed hypersensitivity,
essentially “desensitizing” CD4+ T cells at the site of inflammation. As a result, a system
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is established where new effectors migrate into the inflamed tissue, perform their
function and are subsequently desensitized. This pattern can then continue to effectively
clear a pathogen while maximizing tissue viability (Honda et al., 2014). Similarly, in
chapter 2 of this thesis, the regulation of CD8+ T cell proliferation and survival by PD-1
was different in lymphoid tissues vs. the inflamed site of infection during influenza
infection. PD-1 pathway deficiency led to increased CD8+ T cell proliferation in the
spleen and dLN, but not in the lung. While this robust proliferation resulted in greater
CD8+ T cell numbers in the lung, there was a subsequent increase in cell death of PD-1
pathway deficient CD8+ T cells at the site of infection. These findings are consistent with
the idea that PD-1 can curb immune-mediated damage in inflamed sites by restricting
the proliferation and effector functions of CD8+ T cells. It is interesting that, even in the
absence of PD-1 signals, effector CD8+ T cells in the lung experienced more cell death.
While one contributing factor is likely over-stimulation of PD-1 pathway deficient CD8+ T
cells in lymphoid tissue, it may also be that other regulatory mechanisms in the lung are
activated to prevent immunopathology.
Interestingly, during LCMV clone 13 infection, PD-1 KO P14 cells seem to
preferentially localize to peripheral tissues at very high frequencies during the chronic
phase of infection. It may also be that exhausted CD8+ T cells become “desensitized” at
these sites; however, whether PD-1 is mediating this effect in exhausted CD8+ T cells is
less clear. Overall, it seems that the anatomical location of TCR:antigen stimulation, as
well as the context in which PD-1 engages PD-L1/2, can alter the effects and outcome of
PD-1 inhibition on T cells. It may be that inflammatory cues or other signals at the site of
infection collectively influence the role of PD-1 signals in areas of high pathogen load.
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4.3: Temporal Regulation by the PD-1 pathway
The idea that strength, duration and location of antigen stimulation can impact PD1 mediated inhibition also suggests that PD-1 will have different effects on T cells during
different phases of an immune response. In other words, PD-1 may be playing distinct
roles on naïve, effector, and memory or exhausted CD8+ T cells, which have very
different exposures to TCR:antigen. For example, in an infection setting, PD-1 pathway
signals will be present during initial naïve CD8+ T cell priming in lymphoid tissue.
Previous work has demonstrated that on naïve T cells, PD-1 can impact TCR signaling
cascades, T cell motility, cell cycle progression and, ultimately, effector functions (Parry
and Riley, 2005; Patsoukis et al., 2012; Zinselmeyer et al., 2013; Yokosuka et al., 2012;
Freeman et al., 2000a; Butte et al., 2007). Much of this work has been performed in vitro
and it still remains unclear if identical mechanisms are in place during in vivo T cell
priming. Given the robust expansion of PD-1 deficient CD8+ T cells during the effector
phase (discussed below), it is likely that PD-1 regulates TCR signaling, metabolism, and
cell-cycle progression during in vivo T cell priming.
The work presented in chapters 2 and 3 extend our knowledge of the role of PD-1
during the effector phase of the immune response. In the absence of PD-1, CD8+ T cells
undergo increased proliferation and expansion compared to wildtype CD8+ T cells
during the effector phase of both acutely-resolved influenza infection and chronic LCMV
infection. However, loss of PD-1 signals also resulted in decreased survival of CD8+ T
cells during the contraction phase. These findings demonstrate that a central role for PD1 is to prevent over-activation of CD8+ T cells during the effector phase and to promote
survival CD8+ T cells long-term as they differentiate into memory or exhausted cells.
This tempering of T cell activation during the effector phase is also likely a mechanism to
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prevent immune-mediated damage in the host. Indeed, PD-L1 deficient mice die from
LCMV clone-13 infection between days 7-9 from severe T cell-mediated
immunopathology (Barber et al., 2006).
The data presented in chapters 2 and 3 of this thesis also suggest that early PD-1
signals may not only quantitatively tune activation-induced signals, but also impact the
differentiation pathway of CD8+ T cells. During acutely-resolved influenza infection, early
PD-1 pathway signals seem to promote the development of optimally-functional CD8+
memory T cells. The defect in memory CD8+ T cells in the absence of PD-1 may be due
to selective over-activation and loss of memory precursor cells. However, it could also
be that PD-1 signals qualitatively change the gene expression pattern of CD8+ T cells
early during priming or effector differentiation in a way that promotes memory
development. Given the changes in gene expression observed in PD-L1/2 deficient mice
during influenza infection, it may be that both mechanisms are in place. During LCMV
clone 13 infection, excessive proliferation and cell death in the absence of PD-1 leads to
loss of Tbethi progenitor cells and accumulation of Eomeshi progeny, which corresponds
with altered functionality and durability of exhausted CD8+ T cells. While this is certainly
one mechanism that explains the observed phenotype, it is possible that the resulting
Eomeshi cells also have a different “program” of dysfunction in the absence of PD-1.
Gene expression analysis of these cells should reveal any additional changes in
differentiation status of these PD-1 deficient exhausted CD8+ T cells.
Overall, these findings suggest that early regulation of naïve and/or effector CD8+
T cells can dramatically impact long-term memory or exhausted T cell responses.
Interestingly, previous work has demonstrated distinct regulation of established memory
or exhausted CD8+ T cells by the PD-1 pathway during later stages of infection.
Blockade of the PD-1 pathway on memory cells just prior to re-challenge has been
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demonstrated to improve recall capacity of CD8+ T cells (Erickson et al., 2012, 2014).
Similarly, PD-1/L1 blockade during the chronic phase of LCMV clone 13 infection
improves CD8+ T cell functionality and lowers viral loads (Barber et al., 2006). One
potential explanation for this discrepancy is that PD-1 signals differently in CD8+ T cells
during later stages of infection. Exhausted and memory CD8+ T cells have distinct
transcriptional profiles and changes in the expression of genes involved in signal
transduction and metabolism (Wherry et al., 2007). Thus, making direct extrapolations of
in vitro PD-1 signaling observations to in vivo generated exhausted and memory CD8+ T
cells is not straightforward. In addition, the technical challenges of performing detailed
biochemical analysis of signaling in exhausted CD8+ T cells generated in vivo have
hampered direct interrogation of these questions. Furthermore, it is not known how
different subsets of memory and exhausted cells, with different TCR affinities and levels
of PD-1 expression, are regulated by the PD-1 pathway. Future work should help
elucidate how early PD-1 signals alter the differentiation program of memory and
exhausted CD8+ T cells. It will also be interesting to investigate the potentially different
effects of PD-1 inhibition on naïve, effector, memory or exhausted CD8+ T cells. A better
understanding of how PD-1 regulates CD8+ T cells at different stages of differentiation
and in different phases of the immune responses will inform design of therapeutic
strategies to target the PD-1 pathway.

4.4: Similarities between exhausted PD-1 deficient CD8+ T cells and
exhausted PD-1hi CD8+ T cells in chronic infection
A somewhat unexpected finding of the work presented in chapter 3 of this thesis
is that PD-1 deficiency leads to an exhausted CD8+ T cell pool with similar
characteristics to PD-1hi exhausted CD8+ T cells. Both PD-1 KO and PD-1hi exhausted
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cells are more terminally-differentiated, upregulate several other inhibitory receptors and
have largely lost their ability to produce cytokines and proliferate. However, PD-1 KO
and PD-1hi cells retain cytotoxic ability and also preferentially localize to and accumulate
in peripheral tissues. Transcriptional regulation of these cells seems to occur via high
expression of Eomes and low expression of Tbet (Blackburn et al., 2008; Paley et al.,
2012; Kao et al., 2011). So why do similar states of exhaustion develop in the complete
absence of PD-1 and with the highest levels of PD-1 expression? One hypothesis is that
in this state of terminal-exhaustion, PD-1 signals do not play a significant role in
regulating the functionality or survival of these Eomeshi cells. It may be that Eomeshi
cells do not get stimulated as frequently through their TCR and/or that PD-1 ligation is
less frequent on this cells. The distinct localization of these cells could, in part, support
this idea. Previous work in the lab has demonstrated that sites, such as the bone
marrow, have similar viral clearance to the spleen and blood but lower expression levels
of PD-L1. An idea that has emerged from this finding is that peripheral tissues can serve
as a survival niche for more terminally-differentiated cells that are sensitive to cell death
(Blackburn et al., 2010a). While the levels of PD-L1 may account for this, it could also be
that other inflammatory or survival cues are present in these organs that provide a “safe”
environment for Eomeshi cells. Of note, it is still not clear what signals direct Eomeshi
cells to peripheral tissues and promote their accumulation there. The idea that PD-1
signals are not critical for regulation of Eomeshi cells could also explain the observation
that PD-1hi cells are not responsive to PD-1 pathway blockade.
A complementary hypothesis to explain the similarities between PD-1 KO and
PD-1hi cells is that other inhibitory receptors play a more central role in regulating
Eomeshi cell functions. Both PD-1 KO and PD-1hi cells upregulate the expression and coexpression of CD160, 2B4, and Lag-3 (Blackburn et al., 2009; Paley et al., 2012). It’s
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possible that these or other inhibitory receptors “take over” as the central negative
regulators of terminally-differentiated exhausted cells. It will be interesting to determine if
co-blockade of PD-1 and other inhibitory receptors can potentially re-invigorate PD-1 KO
or PD-1hi cell functions.
Although there are many similarities between PD-1 KO and PD-1hi exhausted
CD8+ T cells, future work should begin to dissect differences between these cell
populations. It may be that other transcription factors play important and distinct roles in
these cell types, including BATF or Blimp-1. Transcriptional profiling of these cells will
provide key insights into these differences and also may inform strategies to improve
functionality of these terminally-differentiated cells.

4.5: How do you most effectively target the PD-1 pathway?
Despite the clear clinical promise and many early successes of PD-1/L1
blockade, the optimal therapeutic approach for targeting the PD-1 pathway remains to
be determined. Transient blockade of PD-1 or PD-L1 can have profound effects on the
re-invigoration of exhausted CD8+ T cell populations during chronic infections and
cancer, including numerical expansion, improved effector function and reduced viral or
tumor burden (Barber et al., 2006; Day et al., 2006; Freeman et al., 2006; Blank et al.,
2005). However, permanent absence of PD-1 did not prevent the development of
exhaustion during chronic LCMV infection, as described in chapter 3. In fact, CD8+ T
cell dysfunction was increased with genetic PD-1 deficiency, resulting in terminalexhaustion and decreased stability of the CD8+ T cell population. These findings have
important implications for different therapeutic clinical approaches since long-term and/or
“maintenance” PD-1 pathway blockade and genetically engineered T cells with altered
PD-1 are being considered in human cancer patients. There are several key questions
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that should be addressed to determine the most effective strategies for use of PD-1
pathway inhibitors in patients.
First, in the experimental model used here, PD-1 signaling is absent for both
CD8+ T cell priming and throughout chronic stimulation.

It remains unclear if PD-1

deficiency has the same effect in different stages of T cell differentiation, as previously
discussed. It may be that loss of PD-1 signals during CD8+ T cell priming is detrimental,
while removing PD-1 during later stages of infection will have more beneficial effects.
The use of ER-Cre PD-1 floxed P14 mice will allow for selective deletion of PD-1 in
CD8+ T cells during various stages of infection to begin to address this question.
Second, it is unclear whether genetic absence of PD-1 is equivalent to antibodymediated blockade. Given the broad expression of PD-1 and PD-1 ligands, blockade of
the PD-1 pathway will likely impact a variety of immune and non-immune cell types. In
fact, unpublished work in our lab has demonstrated that PD-1/L1 blockade not only
impacts CD8+ T cells, but also the frequency of B cells, regulatory T cells, neutrophils,
and other key immune cells (Odorizzi, unpublished data). In addition, some preliminary
studies in ER-Cre PD-1 flox mice have shown that genetic deletion of PD-1 during the
chronic phase of LCMV infection improves CD8+ T cell effector functions to a different
extent than antibody-mediated PD-1 blockade during the chronic phase of infection
(Odorizzi, unpublished data). Therefore, the use of monoclonal antibodies with different
binding affinities and in vivo half lives should be considered carefully, as the prolonged
and complete loss of PD-1 signals may be significantly different than shorter term or
incomplete blockade of the PD-1 pathway. In addition, it should be carefully considered
how prolonged inhibition of PD-1 signals in cancer patients would subsequently impact
their immune responses to vaccination or infection. The data presented here suggest
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that pathogen-specific CD8+ T cell responses will be dysregulated without the PD-1
pathway.
Finally, the impact of prolonged inhibition of the PD-1 pathway may be
considerably different in the presence versus absence of high-level antigen stimulation.
In the current setting of chronic LCMV infection, where the antigen stimulation and
“stress” on the CD8+ T cell compartment is high and constant, absence of a key
negative regulatory pathway may result in T cell over-stimulation.

In setting where

antigen levels have been controlled to a low level, continued loss of PD-1 signals may
be less detrimental to the stability to the T cell population, may promote CD8+ T cell
functionality and may even be beneficial. Future studies will be necessary to dissect
these important and clinically relevant possibilities.

4.6: Biomarkers for successful PD-1-based therapies
One interesting idea that arises from this work is that the effects of losing PD-1
signals can be monitored by changes in the phenotype of virus-specific CD8+ T cells. In
chapter 3 of this thesis, genetic absence of PD-1 leads to a dramatic loss of Tbethi cells
and accumulation of terminally-differentiated, Eomeshi exhausted CD8+ T cells. Although
PD-1 blockade during the chronic phase of infection has different short-term functional
consequences on CD8+ T cells, there is also a significant shift towards Eomeshi PD-1hi
progeny in this setting. In addition, this accumulation of Eomeshi PD-1hi cells can be seen
in the bulk CD8+ T cell population, along with increased Ki67 expression that
accompanies the conversion of Tbethi progenitors into Eomeshi cells. Of note, changes in
Tbet expression seem more challenging to resolve in the bulk CD8+ T cell population
(Odorizzi and Pauken, unpublished data). These findings suggest that expression of
Eomes, PD-1 and perhaps Ki67 could be examined as a way to screen for successful
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induction of immune responses following clinical use of PD-1 pathway blockade. Indeed,
in collaboration with Bob Vonderhide and Andy Minn’s lab, a mouse model of melanoma
was used to demonstrate that successful radiation and checkpoint blockade correlated
with induction of Ki67+ Granzyme B+ Eomeshi PD-1hi cells (Tywman and Rech et al.
Submitted). Thus, the mechanisms of PD-1 mediated exhausted CD8+ T cell inhibition
elucidated in this thesis may provide insight into biomarkers for clinical use.

4.7: Safety of PD-1-based therapies in patients
An additional consideration for the use of PD-1 pathway blockade is the safety of
targeting a molecule with such profound and widespread immunoregulatory functions.
Given the predisposition of pdcd1 deficient mice for autoimmune disease, a major
concern for targeting the PD-1 pathway is the potential for autoimmune side effects
(James et al., 2005; Velázquez-Cruz et al., 2007; Francisco et al., 2010). This is
especially concerning given the off-target effects of CTLA-4 blockade (Ipilimumab) in the
clinic (Pardoll, 2012; Peggs and Allison, 2006). However, while some pulmonary and
gastrointestinal adverse effects have been reported in PD-1/L1 blockade clinical trials,
most patients tolerate PD-1 pathway blockade very well (Brahmer et al., 2012; Topalian
et al., 2012). As we begin to better understand PD-1 pathway regulation of exhausted
CD8+ T cells, it may even be possible to further decrease adverse effects by directly
targeting molecules downstream of PD-1 signaling.
In addition to potential off-target effects, the work presented in chapters 2 and 3
of this thesis also suggests that loss of PD-1 signals may alter CD8+ T cell responses to
subsequent infections or vaccinations. With over 39 clinical trials currently underway with
PD-1/L1 blockade, many patients will be armed with an immune system that has
essentially lost the ability to signal through PD-1 (ClinicalTrials.gov). This may negatively
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impact the formation of memory responses following vaccination, including CD8+ T cell
memory but also potentially B cell and antibody responses (Good-Jacobson et al.,
2010). In addition, exposure to infections may also lead to altered immune responses
and, as a result, pathogen clearance. Future work should investigate these possibilities
in patients who received PD-1 pathway blockade.

4.8 Summary
The work presented in this thesis provides novel insight into the role of PD-1 in
regulating in vivo anti-viral CD8+ T cell responses.

PD-1 plays a prominent role in

regulating effector CD8+ T cell proliferation, expansion and survival, consistent with
previous findings. However, studies in chapters 2 and 3 of this thesis extend these
observations to show that PD-1 also has a previously unappreciated role in shaping the
development and maintenance of long-term memory or exhausted CD8+ T cell
responses. This novel role for PD-1 signals highlights the complex regulation of CD8+ T
cell responses by inhibitory receptors. Specifically, PD-1 balances the need for an
effective anti-pathogen CD8+ T cell response with prevention of immunopathology and
the generation of long-lived memory or exhausted T cell responses. Future studies will
further dissect the molecular mechanisms responsible for the observed effects of PD-1
on effector, memory and exhausted CD8+ T cells. These findings also provide insight
into targeting this clinically relevant pathway and stress the importance of further studies
to better understand PD-1 mediated inhibition of CD8+ T cells and other immune cells.
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